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Improvements in the environmental and occupational conditions as well as advances 
in medical care resulted in an increased life expectancy in the industrialized world. However, 
higher age also comes with an increased risk for neurodegenerative diseases. These 
disorders are accompanied by physical or mental impairments and lead to a long period of 
suffering. Most of the pathogenic causes are still not known, thus no curative therapies are 
available. 
 
1.2. Neurodegenerative disorders 
The progressive damage or death of neurons in the central nervous system (CNS) is 
one of the main reasons for disability in industrialized countries. The underlying disorders 
strongly impair quality of life by deterioration of sensory, motor and higher cognitive 
functions. Neurodegeneration occurs mainly from spontaneous or inherited causes as well 
as from traumatic lesions and is mostly associated with atrophy of the central or peripheral 
nervous system, leading to reduced innervation of the target organs. The most frequently 
occurring neurodegenerative disorders (NDD) are Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and prion 
diseases. Among the induction of neurodegeneration by inherited mutations of certain 
proteins, multifactorial endogenous pathomechanisms, for instance oxidative stress, 
excitotoxicity, protein misfolding and spontaneous mutations can result in protein 
accumulation and lead to the activation of signal-transduction pathways initiating cell death 
(Ross & Poirier, 2004; Hutchins & Barger, 1998; Martin, 2001). For most NDD, no curative 
therapy exists. Even though there are numerous therapies to relieve symptoms of these 
disorders, they cannot prevent the progression of pathology. In the last decades, research 
succeeded in discovering candidate molecules involved in the pathophysiology, but their 
particular roles are still not fully understood (Forman et al., 2004; Prusiner, 2001). Next to 
the necessity to develop strategies to improve symptomatic treatment and to elucidate the 




reasons for neurodegeneration, there is thus prime importance to establish therapies 
counteracting neuronal degeneration and facilitate regeneration. 
 
1.3. Parkinson´s disease 
1.3.1. Epidemiology and phenotype 
The first scientific description of the disorder was done by the British physician James 
Parkinson in 1817, when he examined six patients who showed the core clinical features 
comprising today’s PD symptomatic. This includes resting tremor, flexed posture with a 
tendency to fall, bradykinesia, which is the paucity of voluntary movements and muscle 
rigidity. Moreover, additional symptoms are found in Parkinson’s disease, for instance 
insomnia, dysphagia, urinary incontinence, pain and psychiatric disorders such as depression 
and dementia (Parkinson, 1817; Dexter & Jenner, 2013; Dauer & Przedborski, 2003; Smith et 
al., 2012). In industrialized countries the prevalence of PD is estimated with 0.3% of the 
entire population, but considering that it is an age-dependent disorder with an average 
disease onset at ~60 years, the prevalence increases to 1% in the population older than 60 
years (Lau & Breteler, 2006; Dexter & Jenner, 2013) and is therefore the second most 
frequent NDD after AD. In 5% of the affected patients the disease is inherited in the form of 
point missense mutations and multiplications of certain genes, while in the other 95% the 
disease occurs sporadically (Chartier-Harlin et al., 2004; Singleton et al., 2004; Federoff et al., 
2003; Dauer & Przedborski, 2003). 
 
1.3.2. Anatomical background and pathophysiology 
Parkinson’s disease is a system disorder involving many parts of the brain. It’s best-
known pathological hallmarks include the prominent loss of dopaminergic neurons in the 
substantia nigra (SN) in the midbrain, although the degeneration is not limited to this neuron 
type (Pillon et al., 1989; Pereira et al., 2012). These dark pigmented dopaminergic neurons, 
containing neuromelanin, are part of the basal ganglia and involved in complex regulatory 
circuits of voluntary movements. From the cell bodies located in the substantia nigra pars 
compacta (SNpc) the unmyelinated axons project into the striatum, which is divided in the 
putaminal part and the caudate nucleus. Dopaminergic terminals provide input to the spiny 




striatal neurons and therefore modulate the activity of striatal cells mediated by two 
dopamine receptors D1 and D2 (Kandel et al., 2000; Purves et al., 2004). They provide 
excitatory input mediated by D1 type receptors on spiny cells targeting the internal globus 
pallidus (GPi) via the direct pathway, while D2 type receptors mediate inhibitory input on the 
spiny neurons and thereby inhibit activity of the external globus pallidus (GPe). Repressing 
input in the GPe leads to excitatory outputs of the subthalamic nucleus that in turn projects 
to the GPi and represents the indirect pathway. Afferent fibers of the GPi target the ventral 
nucleus of the thalamus that projects to the frontal cortex and back to the spiny neurons of 
the striatum (Parent & Hazrati, 1995; Obeso et al., 2002; Crittenden & Graybiel, 2011). The 
interconnection of cortical inputs into the striatum and substantia nigra pars reticulata 
(SNpr) mirrors the complexity and importance of these regulatory circuits to generate 
voluntary movements. Any imbalance in transmitter levels targeting the striatal spiny 
neurons leads to more or less pronounced motor dysfunctions. Therefore, degeneration of 
nigral dopaminergic neurons leads to dopamine depletion in the striatum and generates the 
characteristic symptoms of PD by underactivation of the GPi (Bernheimer et al., 1973; 
Hornykiewicz, 2001; Bergman & Deuschl, 2002; Obeso et al., 2002; DeLong & Wichmann, 
2007) (see Figure 1.1.: Schematic diagram of the direct and indirect pathways of the basal 
ganglia in normal and PD conditions, from Smith et al., 2012). Due to the fact that the 
terminal loss of dopaminergic fibers is much more pronounced in the striatum than the 
dopaminergic cell death in the SNpc, it is assumed that the degeneration of the nigrostriatal 
system follows a dying back mechanism, starting at the axonal terminals and involves 
mechanisms of axonal degeneration (Burke & O’Malley, 2013; Tönges et al., 2012). 
 





Figure 1.1: Scheme of the direct and indirect circuits of the basal ganglia in healthy and PD conditions. Red 
arrows denote inhibitory and blue arrows indicate excitatory input in the target area. The thickness of arrows 
signifies the strength of transmission. Eliminating output from the SNpc in Parkinsonism (right diagram), 
changes the transmission strength in the following structures resulting in less cortical input (modified from 
Smith et al., 2012). 
 
1.3.3. Etiology 
1.3.3.1. Lewy bodies and their contents 
At the time of clinical disease onset, around 50% of the dopaminergic neurons are 
already degenerated, resulting in motor dysfunction (Fearnley & Lees, 1991). One of the 
disorder’s hallmarks discovered in 1912 by Friedrich Lewy, is the presence of intra 
cytoplasmatic inclusion bodies, later called Lewy bodies (LBs), which are found in the 
remaining dopaminergic neurons and their neurites in the SNpc, but also in other parts of 
the brain (Forman et al., 2004; Gibb & Lees, 1988; Dickson et al., 2009). The role of the Lewy 
body, which also occur in other so-called Lewy body diseases, is still under debate. Following 
the theory of Braak, who proposes a staging of PD based upon an expanding LB load from 
the brainstem to cortical structures, they are have a detrimental function inducing neuronal 
death during disease progression (Braak et al., 2003; Braak & Braak, 1991; Braak et al., 
2003). On the other hand, in regard to their composition consisting mainly of 
neurofilaments, ubiquitin and alpha-synuclein and their wide distribution throughout the 




brain, LBs could also have protective properties by isolating toxic material from the 
surrounding cytoplasm and therefore promoting survival of the LB-containing neurons 
(Tompkins & Hill, 1997; Burke & Barnes, 2006; Parkkinen et al., 2011). 
 
1.3.3.2. Alpha-synuclein 
 In 1997, Maria G. Spillantini discovered the main component of LBs, which is the 140 
amino acid protein alpha-synuclein (Spillantini et al. 1997; Spillantini et al. 1998). Normally, 
this soluble protein is abundantly localized in the cytosol and presynaptic nerve terminals. 
The physiological role of alpha-synuclein is associated with the SNAREing of synaptic vesicles, 
reversibly linking them to membranes by containing an N-terminus similar to 
apolipoproteins (Sidhu et al., 2004; Lashuel et al., 2013; Chandra et al., 2003). Additional 
functions are very likely and not yet completely understood. 
Alpha-synuclein protein mutation or misfolding leads to aggregation of cytosolic 
oligomer and protofibrillar alpha-synuclein, which is widely accepted to be the toxic species 
of this protein. Thus, it is likely that fibrils, which are encased in the LBs, are less toxic (Choi 
et al., 2013; Rochet et al., 2004; Bucciantini et al., 2002). In the alpha-synuclein encoding 
gene (SNCA) there are five alpha-synuclein missense mutations causing PD known today: 
A53T, A30P, E46K and the recently discovered G51D and H50Q (Kiely et al., 2013; Proukakis 
et al., 2013). Mutations and polymorphisms in the SNCA gene can lead to the inherited 
disease by favouring the formation and accumulation of oligomeric and fibrillar structures 
(Lashuel et al., 2013; Chartier-Harlin et al., 2004; Lázaro et al., 2014). In addition to 
mutations or multiplications in the SNCA gene, other mutated proteins were discovered to 
cause the rare forms of familiar PD, e.g. Parkin, Pink1, LRRK2, DJ-1 and ATP13A2 (Burke & 
O’Malley, 2013; Dawson & Dawson, 2003; Dexter & Jenner, 2013). 
 
1.3.3.3. Oxidative stress 
Dysfunction of proteins can also be triggered by oxidative stress generated by 
reactive oxygen species (ROS), catalyzed by transition metals or the dysfunctional production 
of ATP from the mitochondrial respiratory chain complex I. Mitochondria normally release 
powerful oxidants as by-products of energy production, but it is still not clear whether the 




impairment of complex I is the cause or the consequence of neurodegeneration (Yan et al., 
2013; Dauer & Przedborski, 2003; Blesa et al., 2012; Dexter & Jenner, 2013). 
The specific vulnerability of dopaminergic neurons in PD could result from different 
additional factors: The neurotransmitter dopamine is degraded by enzymatic deamination 
through monoamine oxidases (MAOs) producing 3,4-dihydroxyphenylacetic acid (DOPAC) 
and H2O2. The interaction of transition metals and H2O2 results in the production of toxic 
hydroxyl radicals while dopamine can be oxidized and form quinines, superoxide free 
radicals and hydrogen peroxide (Sidhu et al., 2004). Excess dopamine amounts and the 
consequent generation of toxic quinones and semiquinones are prevented by the removal of 
excessed catecholamines from the cytosol in the synthesis of neuromelanin, which occurs as 
a characteristic substance in dopaminergic neurons of the SN (Graham, 1978). Additionally 
to remove excess catecholamines from the cytosol, it chelates redox-active metals by 
forming complexes and therefore reducing the production of hydroxyradicals (Zecca et al., 
2003). Therefore, the combination of mitochondria-related energy failure, dysfunctional 
neuromelanin synthesis leading to ROS production from dopamine metabolism and altered 
scavenging capacity of transition metal levels may contribute equally to neurodegeneration 
of especially nigral dopaminergic neurons. 
 
1.3.3.4. Glial reactions in PD 
Another hallmark in neurodegenerative disorders is the accompanying glial 
infiltration to the damaged region. In the healthy brain microglia are found throughout the 
parenchyma and are constantly active. Their ramified processes scan the extracellular space 
for cues revealing injury. After sensing, microglia move to the place of damage, where they 
agglomerate and become phagocytotic to remove cell debris from injury (McGeer & 
McGeer, 2008; Hanisch & Kettenmann, 2007). This inflammatory reaction occurs also in the 
SN of PD patients and it was shown that microglia infiltration evokes dopaminergic cell 
damage in vitro and in vivo. After activation, microglia are thought to produce large amounts 
of superoxide radicals, which in turn could be responsible for dopaminergic damage via 
oxidative stress (Hirsch & Hunot, 2009; Hunter et al., 2007; McGeer & McGeer, 2008; Su et 
al., 2009; Kim & Joh, 2006). 




The role of astrocytes in the lesioned CNS is also not completely elucidated yet. Some 
of the normal functions of astrocytes in the brain are the maintenance of neurons by supply 
with essential nutrients and neurotrophic factors, the regulation of ion concentrations and 
the uptake and metabolism of extracellular neurotransmitters (Maragakis & Rothstein, 
2006). After injury, activated astrocytes are building a wall-like structure in damaged 
regions, the so-called astrogliosis. In PD, astroglia seems to play a neuroprotective role 
against oxidative stress, depending on the quantity of the antioxidatively acting enzyme 
glutathione peroxidase, which was inversely correlated with the severity of dopaminergic 
degeneration in human post mortem brains (Damier et al., 1993). 
 
1.4. Current treatment of PD and future approaches 
1.4.1. Symptomatic treatment 
Until now there is no curative treatment for PD available and the medication used in 
PD is merely symptomatic. Available treatments to attenuate symptoms of PD are usually 
orally applied, for example dopamine agonists, levodopa (as the precursor of dopamine 
biosynthesis), monoamine oxidase B (MAOB) inhibitors (to prevent dopamine degradation 
after release) and anti-glutamatergic or anti–cholinergic substances to adjust transmitter 
levels in the basal ganglia. Alternatively, some substances can be delivered continuously via 
subcutaneous or intrajejunal infusions (Dunnett & Björklund, 1999; Obeso et al., 2010). Deep 
brain stimulation is reserved for more advanced cases of the disease (Deuschl & Bergman, 
2002; Stefani et al., 2007). 
 
1.4.2. Future approaches 
One of the difficulties in PD therapy arises from the very late onset of motor 
symptoms, when already more than the half of the nigrostriatal projections is degenerated 
(Bernheimer et al., 1973). Because until now there is no biomarker approved that can 
predict onset of motor symptoms, the main challenge would be to either prevent the 
remaining neurons from further degeneration or to facilitate restorative neuronal growth 
after diagnosis of PD. 




1.4.2.1. Regenerative strategies 
There are several approaches to prevent neurons from dying as well as to enhance 
neuronal regeneration in vivo and in vitro. It is now also established that also adult aged 
neurons have the intrinsic ability to sprout, although it is lower than in young or even 
embryonic neurons (Fawcett, 1992; Verma et al., 2005). In animal models of PD re-
innervation of the striatum by nigral dopaminergic fibers was observed after toxin-induced 
nigrostriatal degeneration (Hagg & Oudega, 2006; Finkelstein et al., 2000; Mitsumoto et al., 
1998). One indicator of regenerative growth or sprouting of neurons in the CNS is the 
expression of growth associated proteins (GAP), such as GAP-43, which is known to regulate 
membrane motility and neuronal plasticity by modulating F-actin polymerisation (Schmidt, 
2004; Laux et al., 2000). Thus, the lesioned dopaminergic system generally has the ability to 
regenerate, but it is unclear whether compensatory regeneration takes place in Parkinson’s 
disease brains or if this mechanism is impaired in pathology.  
 
1.4.2.2. Neurotrophic factors 
The application of neurotrophic factors (NTF) in several pre-clinical studies revealed a 
promising potential to facilitate nigrostriatal restoration, but these approaches mostly failed 
in human trials (Aron & Klein, 2011; Hidalgo-Figueroa et al., 2012; Winkler et al., 1996). 
Nevertheless, there were single promising results in cases of unilateral intrastriatal infusion 
of the glial cell-line derived neurotrophic factor (GDNF), which is essential for development 
and survival of dopaminergic neurons in vitro and in vivo (Tomac et al., 1995; Kirik et al., 
2004; Clarkson et al., 1997).  For example, the putaminal infusion in a 62-year old PD patient 
with advanced disease resulted in improved motor performance within 24 months after 
continuous infusion. Post mortem immunohistology demonstrated a local increase in  
tyrosine hydroxylase (the rate limiting enzyme for dopamine synthesis and marker for 
dopaminergic neurons), accompanied by enhanced immunoreactivity for growth-associated 
protein-43,which speaks in favour of fiber sprouting to the treated side (Love, 2005). 
 
 




1.4.2.3. Overcoming growth restricting obstacles 
Extracellular cues from surrounding cells, e.g. astroglia or oligodendrocytes, are 
involved in growth inhibition and provoke regenerative failure (Kottis et al., 2002; Cafferty et 
al., 2010; Yiu & Zhigang, 2009). Via neuronal surface receptors growth inhibitory signaling 
cascades are activated involving Rho associated kinase (ROCK), which results in the 
stabilization of the dynamic actin cytoskeleton and growth cone collapse (Gehler et al., 2004; 
Gallo & Letourneau, 2004; Mueller et al., 2005). Recently our group could show that ROCK 
inhibition improves regenerative neurite outgrowth, axonal regeneration and neuronal 
survival in different in vitro and in vivo models of optic nerve trauma, Parkinson’s disease 
and amyotrophic lateral sclerosis (Lingor et al., 2007; Bermel et al., 2009; Tatenhorst et al., 
2014; Tönges et al., 2012; Günther et al., 2014; Tönges et al., 2014). Pharmacologically 
induced ROCK inhibition via the small molecule inhibitors fasudil or Y-27632 stimulated 
cytoskeleton reorganization, neurite outgrowth and axonal regeneration, while the 
improved survival was mediated by the activation of survival cascades, e.g. Akt/PKB, which 
were also activated by trophic factors, such as the ciliary neurotrophic factor (CNTF) (Chadi 
et al., 1993; Peterson et al., 2000) in vitro and in vivo (Lingor et al., 2007; Lingor et al., 2008; 
Bermel et al., 2009). 
In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and the 
6-hydroxydopamine (6-OHDA) toxin-induced animal models of PD, the respective toxin is 
applied systemically (MPTP) or via intracranial injection (6-OHDA). MPTP crosses the blood 
brain barrier and the MAO-B from astrocytes subsequently metabolizes it into its active ion 
MPP+. 6-OHDA, on the other hand, has to be applied directly to the brain area of interest. 
Both active toxins are taken up into dopaminergic cells via the dopamine transporter (DAT), 
where they inhibit the complex I of the mitochondria, which leads to production of ROS, 
oxidative stress, energy failure and consequently to the degeneration of the dopaminergic 
cell (Cannon & Greenamyre, 2010; Blesa et al., 2012; Dauer & Przedborski, 2003).  
As we could previously demonstrate, the pharmacological ROCK inhibitor fasudil 
induced enhanced dopaminergic cell survival in the SN of MPTP intoxicated mice, 
accompanied by a preservation of dopaminergic terminals in the striatum and improved 
motor performance of the animals (Tönges et al., 2012). Additionally, in the 6-OHDA model, 
ROCK inhibition via fasudil resulted in increased striatal DOPAC levels at 12 weeks after 
intoxication, indicating regenerative sprouting (Tatenhorst et al., 2014). 




ROCK inhibition via fasudil or Y-27632 not only results in beneficial effects on 
neurons, but also on astrocytes and microglia (Lau et al. 2012; Barcia et al. 2012; Yu et al. 
2010; Monnier et al. 2003). Here, pharmacological inhibition of ROCK induces a 
morphological change in astrocytes, accompanied by determined changes in the astrocytic 
transcriptome, as for example the increase in the expression levels of the brain derived 
neurotrophic factor (BDNF) and the excitatory amino acid transporters (EAATs), indicating a 
astrocytic phenotype which supports neuronal survival (Lau et al. 2012; Lau et al. 2011). 
Furthermore, pharmacological ROCK inhibition resulted in reduced numbers of microglia 
engulfing dopaminergic neurons and attenuated cell loss in the MPTP animal model of PD, 
suggesting a preservation of degenerating neurons from phagocytotic elimination by 
activated microglia in regions of nigrostriatal cell death (Barcia et al. 2012; Villar-Cheda et al. 
2012). 
 
1.4.2.4. The ROCK signaling cascade 
ROCK is a serine/threonine (Ser/Thr) protein kinase with a molecular mass of 160 
kDa. Two different genes encode two ROCK isoforms: ROCK1 (or ROCKβ) is mainly expressed 
in non-neuronal tissue, but it is also found in synaptic structures of motoneurons in the rat 
brain, while ROCK2 (or ROCKα) is the dominant isoform in neurons of the vertebrate brain 
(Gonzalez-Forero et al., 2012; Komagome et al., 2000; Hashimoto et al., 1999) although its 
abundance in the human brain is not sufficiently investigated yet.  
The catalytic domain of ROCK is located at the amino terminus, while the carboxyl 
terminus contains a pleckstrin-homology region with a cysteine rich-repeat sequence. The 
central part encompasses a coiled-coil-forming domain, containing the domain binding site 
for the GTP-bound Rho (RBD), which is the activator of ROCK. In the absence of GTP-Rho 
ROCK is forming an auto-inhibitory loop by the binding of the C-terminus to the kinase 
domain. In this conformation ROCK is inactive (Ishizaki et al., 1996; Shi & Wei, 2008; Mueller 
et al., 2005).  
The extraneuronal cellular composition in the CNS is a major limitation for 
regeneration mainly mediated by extracellular signaling from myelin or lesion-induced scar 
tissue via the ROCK cascade (Yiu & Zhigang, 2009; Mueller et al. 2005). These extracellular 
cues consist of myelin-associated proteins, such as Nogo-A, myelin-associated glycoprotein 




(MAG), oligodendrocyte-myelin glycoprotein (OMgp) and several proteoglycans as well as by 
ephrins, semaphorins and chondroitin sulphate proeteoglycans (CSPGs), which are either 
normally expressed in CNS or upregulated after brain injury, for example in oligodendrocytes 
and astrocytes (Cafferty et al., 2010; Kottis et al., 2002; Yiu & Zhigang, 2009; Goldshmit et al., 
2006; Goldberg et al., 2004; Monnier et al., 2003).The binding of the myelin-associated 
ligands to a neuronal receptor complex, comprising the Nogo receptor 1 (NgR1), the leucine 
rich repeat and lg domain-containing Nogo receptor-interacting protein-1 (LINGO-1) and the 
p75 neutrophin receptor (p75NTR) or TROY, on the neuronal surface results in the 
transformation of the inactive GDP-bound small GTPase RhoA into the active GTPase RhoA 
(Mi et al., 2004; Dudek & Garcia, 2003). The phospholipid lysophosphatidic acid (LPA) as well 
as sphingosine-1-phosphate (S1P), which can be secreted from various cells and are present 
in several biological fluids (Eichholtz et al., 1993; Fyrst & Saba, 2011), can stimulate the 
neuronal G-protein-coupled receptor (GPCR), which leads to the activation of GTPase RhoA 
(Goetzl, 2007; Seasholtz et al., 1999). Activated GTPase RhoA is binding at the RhoA binding 
domain of ROCK, causing thereby a conformational change of the kinase by abandoning its 
auto-inhibitory conformation and turning it into the active state (Amano et al., 2010; Ishizaki 
et al., 1996; Mueller et al., 2005). ROCK activation leads to an increased kinase activity, a 
translocation to cellular membranes and to phosphorylation of diverse target proteins. One 
of the main downstream targets is the myosin light chain (MLC), which is directly 
phosphorylated by ROCK and thereby stimulating interaction of actin-myosin contractility 
and the formation of stress fibers (Totsukawa et al., 2000; Raad et al., 2012). Additionally, 
ROCK activity leads to phosphorylation of the MYPT1 subunit of the myosin light chain 
phosphatase (MLCP), that results in less MLCP activity and therefore indirectly in increased 
amounts of phosphorylated MLC (Amano et al., 2010; Shi & Wei, 2008). Another function of 
ROCK is to phosphorylate LIM-kinase and therefore increase its activity leading to more 
kinase activity towards the small actin-depolymerization factor cofilin, which in turn is 
inactivated by phosphorylation and stopped in its activity, what results in stress fiber 
formation and growth cone collapse (Maekawa, 1999).  Active cofilin is maintaining a rapid 
filament assembly and disassembly of filamentous actin (F-actin) at the so called pointed 
ends by generating G-actin monomers through depolymerization at low concentrations of 
monomeric actin (Meyer & Feldman, 2002). 




Further downstream targets of ROCK are the collapsing response mediator protein 2 
(CRMP2), which plays an essential role in semaphorin-mediated axonal guidance during CNS 
development (Mueller et al., 2005) and proteins associated with the interconnection of the 
F-actin cytoskeleton and the plasma membrane, such as adducin or ezrin, radixin and moesin 
(ERMs) (Rêdowicz, 2002). ERMs are required for the formation of focal adhesion complexes 
and stress fibers, regulating cell-cell-junction dynamics, membrane ruffling and cell motility 
(Arpin et al., 2014). In regard to its function in synapses, ROCK is also thought to modulate 
dynamic neuronal physiology, neurotransmitter release and electrical activity (Gonzalez-
Forero et al., 2012). The actin cytoskeleton builds a stable, intricate network of several 
synaptic protein-protein interactions that is closely linked to synaptic vesicles and active 
zones and thereby modulating the guidance of synaptic vesicles to the plasma membrane 
(Dillon & Goda, 2005; Brodin et al., 2000; Morales et al., 2000; Sakaba & Neher, 2003). There 
is evidence that ROCK activity is necessary to maintain transmitter release and the motor 
output on presynapses from hypoglossal motoneurons in vitro (Gonzalez-Forero et al., 
2012), but the exact underlying mechanisms are not fully understood. 
Apart from the regulation of the cytoskeleton, ROCK signaling is involved in protein 
synthesis and cell survival. The protein tyrosine phosphatase and tensin homolog (PTEN) 
mediated survival cascades are well-known from cancer studies, where PTEN activation 
leads to tumor suppression (Guertin & Sabatini, 2007; McCarroll et al., 2014). However, 
PTEN can be also directly phosphorylated by ROCK (Li et al., 2005), which leads to a decrease 
in intracellular levels of phosphatidylinositol (3,4,5) triphosphate (PI(3,4,5)P3) by 
dephosphorylation leading to decreased activity of the serine-threonine kinase Akt, which in 
turn regulates the activity of Ras homolog enriched in brain (Rheb) (Meier et al., 2009; 
Dudek et al., 1997; Stambolic et al., 1998). Briefly, ROCK indirectly decreases the Rheb 
activity resulting in the inhibition of the mammalian target of rapamycin (mTOR) subunit 
mTORC1, thereby suppressing signals for cell growth and survival by negatively controlling 
mRNA translation, ribosome biogenesis, autophagy and metabolism (Guertin & Sabatini, 
2007; Park et al., 2011). Furthermore ROCK inhibition decreases cleaved caspase3 activity 
and therefore leads to suppression of caspase3 mediated apoptotic signaling (Koch et al., 
2014). The upstream activators and downstream targets of ROCK are summarized in Figure 
1.2. 
 




                
 
Figure 1.2: Scheme summarizing upstream activators and downstream targets of ROCK. Binding extracellular 
ligands propagate growth inhibitory cues through RhoA activation to activate ROCK (green). Phosphorylation of 
downstream targets (green) leads to actin cytoskeletal reorganisation, which results in stress fiber formation 
and growth cone collapse. Next to PTEN phosphorylation, ROCK activity furthermore results in negative 
regulation of downstream proteins (red), leading via mTORC to suppression (light grey) of cell growth and 
survival. These pathways might all be inverted after ROCK inhibition leading to axon outgrowth, cell growth and 
survival (modified from Koch et al., 2014). 
 
1.4.2.5. ROCK inhibition via fasudil 
The important role of the ROCK signalling cascade for survival and growth of neuronal 
cells became clear by inhibiting its activity with different substances. One of these ROCK 
inhibitors is the isoquinoline derivative fasudil, which in Japan is in clinical use since 1995 for 




the treatment of cerebral vasospasms following subarachnoid haemorrhage (Mueller et al., 
2005). After fasudil administration over a time period of 14 days, patients suffering from 
severe subarachnoid haemorrhage showed reduced vasospasm and there were decreased 
numbers of patients with vasospasm-related clinical deterioration (Shibuya et al., 1992). 
Additionally, fasudil treatment was also employed in patients suffering from a stable angina 
pectoris, resulting in prolonged exercise time in the treadmill exercise testing without blood 
pressure and heart rate change (Shimokawa et al., 2002). Fasudil treatment was well 
tolerated in both studies and did not cause any serious side effects. In treatment of 
vasospasm fasudil operates via ROCK inhibition and the activation of MLCP, thereby 
antagonistically modulating the calcium sensitization for the Ca2+-depending muscle 
contraction and preventing vascular smooth muscle from inappropriate coronary 
hypercontraction, presumably caused by enhanced ROCK expression, which was also 
observed in a porcine model for vasospasms (Shimokawa et al., 2002). 
As mentioned above, ROCK inhibition via fasudil leads in pre-clinical studies to 
attenuated neuronal cell loss and to enhanced neurite regenerative responses in different 
cell culture trials and in vivo models for neurode- and regeneration (Lingor et al., 2007; 
Lingor et al., 2008; Bermel et al., 2009; Tatenhorst et al., 2014; Tönges et al., 2012; Günther 
et al., 2014; Tönges et al., 2014, see 1.3.: Treatments of PD and promising candidates). 
However, fasudil is not a completely specific ROCK inhibitor. There is no special selectivity 
for ROCK1 and ROCK2 (Tang et al., 2013) and it was shown that fasudil affects several other 
kinases, for example AMP-activated protein kinase (AMPK) or phosphorylase kinase (PHK) 
(Davies et al., 2000; Cohen, 2002). Therefore it is important to first delineate the pro-
regenerative effects and the neuroprotective mechanisms observed in vitro and in vivo more 
particularly to the specific inhibition of the Rho kinase in order to understand more about 
the mode of action of fasudil. Because it is used in Japan as licensed medication in humans, 
the safety profile and the pharmacokinetic behaviour is well-known, which makes fasudil a 
promising candidate for further evaluation in the treatment of neurodegenerative diseases.  
 
1.4.2.6. Viral vector gene transfer 
Viral vectors are employed to deliver particular DNA sequences into cells in vitro and 
in vivo due to their ability to infect cells and express their genome. The usage of adeno-




associated viral (AAV) vectors seems to be a safe tool, since the wild-type virus is not causing 
disease in mammals per se (During & Leone, 1995; Flotte & Carter, 1995). The serotype of a 
virus confers different transduction properties dependent on the affinity and presence of 
specific receptors for AAV capsids (Tenenbaum, 2004). For example, it has been shown that 
<5% of all transduced cells after stereotactical injection of the serotype AAV2 into the mouse 
striatum or substantia nigra are glia cells, while virtually all transfected cells were neurons 
(Tenenbaum et al., 2003; Bartlett et al., 1998; McCown et al., 1996; Klein et al., 1999). 
Next to the introduction of foreign DNA sequences into the target cells, there is also 
the possibility to interfere with the cell genome by viral vectors resulting in the expression of 
small hairpin RNAs (shRNA) (Reynolds et al., 2004). Once introduced into the cell, the 
shRNAs are recognised by a RNase III family nuclease called Dicer and processed into 
functional siRNA, which enables complete pairing with the messenger RNA (mRNA) of the 
target gene followed by subsequent degradation of the target transcript (Cheng et al., 2003; 
Paddison et al., 2002). The introduction of viral vector-mediated RNA interference offers the 
possibility to target selected genes from particular cells downregulating their expression 
without regulating the transcription of other genes.  
 
1.5. Aims and goals 
Because Parkinson’s disease can be diagnosed only when the characteristic motor 
symptoms occur following the degeneration of more than half of the nigrostriatal 
projections, it is of great interest to find ways to impede further cell loss and to facilitate 
neuronal regenerative responses to stop disease progression and to restore impaired motor 
functions.  
In order to evaluate whether there is a specific intrinsic regeneration failure in 
dopaminergic neurons, in this work, human brain sections were examined by 
immunohistochemistry. To this, the expression levels and distribution of growth-associated 
proteins and the growth-inhibitory ROCK protein were evaluated in the brains of patients, 
who suffered from Parkinson’s disease as well as from young and age-matched controls post 
mortem.  
In the second part of the thesis, I focused on the role of ROCK2 in an animal model 
for PD. From recent studies we already knew that pharmacological inhibition of ROCK results 




in prolonged survival and improved regeneration in models of neurodegeneration in vitro 
and in vivo. Now we wanted to determine, if these effects were specifically mediated by the 
regulation of the ROCK2 isoform. Since there was no specific pharmacological inhibitor for 
ROCK2 available, we used viral vector-mediated introduction of a ROCK2 small-hairpin RNA 
(ROCK2-shRNA) into the substantia nigra of 6-OHDA-intoxicated mice to study the neuron-
specific effect of ROCK2-downregulation on dopaminergic survival and degeneration. The 
unilateral striatal injection of the toxin and the ipsilateral introduction of the ROCK2-shRNA 
therefore enabled the investigation of specific neuronal effects of ROCK2-gene silencing on 
dopaminergic neuron with prime relevance to PD. 
 In the last part, I wanted to elucidate the impact of long-term ROCK inhibition 
especially on synaptic vesicle dynamics. Investigating the mode of action of fasudil on the 
synaptic actin cytoskeleton in primary hippocampal neuron cultures would give us further 
insights into the mechanistic action of ROCK inhibition. This is interesting, because the 
effects of ROCK inhibition on neurotransmitter release and signal transmission in neuronal 
circuits could additionally play an important role in the treatment of PD and other 













2. Materials and Methods 
 
2.1. Materials 
2.1.1. List of companies 
Abcam (Cambridge, UK); Agfa (Köln, Germany); Applichem (Darmstadt, Germany); Beckman 
Coulter Inc. (Krefeld, Germany); Biochrom (Berlin, Germany); BIO-RAD (München, 
Germany); Biozol (Eching, Germany); Braun (Melsungen, Germany); Calbiochem, by Merck 
Millipore (Darmstadt, Germany); Canon (Krefeld, Germany); Carl Zeiss Microimaging 
(Göttingen, Germany); Cell Signalling Technology (Cambridge, UK); Charles River (Sulzfeld, 
Germany); Corel Corporation (Ottawa, Canada); Cytoskeleton Inc. (Denver, USA); DAKO 
(Hamburg, Germany); David Kopf Instruments (Tujunga, USA); Dianova (Hamburg, 
Germany); Dionex, by Thermo Fisher Scientific GmbH (Dreieich, Germany); Dremel 
(Leinfelden-Echterdingen, Germany); Ecuphar (Greifswald, Germany); Eppendorf (Wesseling-
Berzdorf, Germany); ESA (Bedfort, USA); Fluka (Steinheim, Germany); GE Healthcare 
(Chalfont St. Gilles, UK); Gibco (Karlsruhe, Germany); GMI (Minnesota, USA) GraphPad 
Software Inc. (La Jolla, USA); Hitachi GmbH (Düsseldorf, Germany); IVC, Tecniplast 
(Hohenpeißenberg, Germany); Jackson ImmunoResearch Laboratory Inc. (Suffolk, UK); 
KyensLab Incorporated (Tokyo, Japan); Leica Microsystems (Mannheim, Germany); Lonza 
(Köln, Germany); Lc Labs (Woburn, USA); Micro Bright Field Inc. (MBF, Colchester, VT, USA); 
Medistar (Ascheberg, Germany); Menzel (Braunschweig, Germany); Merck (Darmstadt, 
Germany); Millipore (Darmstadt, Germany); N.I.H. (Bethesda, USA); Nikon Instruments 
(Düsseldorf, Germany); Noldus (Wageningen, the Netherlands); Okolab (Pozzuoli, Italy); PAA 
(Pasching, Germany); Precellys by Peqlab (Erlangen, Germany); Roth (Karlsruhe, Germany); 
Santa Cruz (Heidelberg, Germany); Sarstedt (Nümbrecht, Germany); Sigma Aldrich 
(Taufkirchen, Germany); Serotec (Oxfort, UK); Serumwerk (Bernburg, Germany); Synaptic 
Systems (Göttingen, Germany); Systat Software GmbH (Erkrath, Germany); Teclapharm 
(Lüneburg,Germany); The MathWorks Inc. (Natick, USA); Thermo Scientifc (Waltham, USA); 
UgoBasile (Comerio, Italy); Vector Laboratories (Burlingame, USA); Wako Pure Chemical 
Industries (Neuss, Germany); World Precision Intruments (WPI, Berlin, Germany); 
Worthington (Lakewood, NJ, USA); Zytomed (Berlin, Germany) 
 





6-OHDA (Sigma) glutamine (Lonza) 
5-Fluoro-2´-desoxyuridine (Sigma) glycerol (Roth) 
30% H202 (Applichem) glycine (Applichem) 
0,9% saline (Braun) H3BO3 (Sigma) 
apomorphine (Teclapharm) HBSS (Gibco) 
APS (Sigma) HClO4 (Merck) 
acrylamide (Applichem) HCl (Roth) 
B-27 Supplement (Gibco) HEPES (Applichem, Merck) 
Bepanthene (Braun) Histoacrylic glue (Braun) 
BSA (Applichem) HNO3 (Sigma) 
BSA, immunoglobulin and protease free 
(Jackson ImmunoResearch Laboratory Inc) 
HPLC water (Merck) 
CaCl2 (Merck) HS (Biochrom) 
C2H4O2 (Roth) Isopropanole (Applichem) 
C6H8O7*H2O (Roth) KCl (Merck) 
DAB peroxidase substrate Kit, SK-4100 
(Vector laboratories) 
ketamine (Medistar) 
DAPI (Sigma) L-AA (Sigma) 
DMEM (Gibco, PAA) L-Cysteine (Fluka) 
DPX (Fluka) luminol (Calbiochem) 
Dual Proteine Standard (BIO-RAD) MEM (Gibco) 
EDTA (Applichem, Merck) Metapyrin (Serumwerk) 
ethanol absolute (Applichem, Merck) methanol (Applichem, Roth) 
ethanol denatured (Applichem, Merck) mineral oil (Sigma) 
fasudil (Lc Labs) MgCl2 (Merck) 
FCS (Biochrom, PAA) mowiol-488 (Merck, Sigma) 
G-actin/F-actin in Vivo Assay Kit 
(Cytoskeleton Inc.) 
Na2B4O7 (Sigma) 
glucose (Merck) NaCl (Merck) 
GlutaMAX Supplement (Gibco) NaHCO3 (Merck) 
Na2HPO4 (Merck) uridine (Sigma) 




NaN3 (Sigma) VECTASTAIN ABC Peroxidase standard Kit, 
PK-4000 (Biozol) 
NaO2C2H3 (Roth) Xylazine (Ecuphar) 
NAOH (Applichem) xylene (Sigma) 
NDS (Jackson ImmunoResearch Laboratory 
Inc.) 
 
Neurobalsal-A medium (Gibco)  
NGS (PAA)  
NH4Cl (Merck)  
non-fat dried milk (Applichem)  
papain suspension (Worthington)  
p-cumaric acid (Applichem)  
Pen/Strep (Lonza, PAA)  
PFA (Applichem, Roth)  
PBS (Applichem, Roth)  
PLL (Sigma)  
SDS (Applichem)  
Sodium octasulfonic acid (Fluka)  
Sterofundin (Braun)  
sucrose (Applichem)  
sudan black (Applichem)  
TEMED (Roth)  
thionine acetate (Sigma)  
ToxiLight™ Non-destructive Cytotoxicity 
BioAssay Kit (Lonza) 
 
TRIS (Applichem)  
tritonX 100 (Applichem, Merck)  
trypsin (PAA)  
trypsin inhibitor (Sigma)  
tween20 (Applichem)  






Anti-ED1 (CD68): from mouse, monoclonal (Serotec) 
Anti-glial fibrillary acidic protein (anti-GFAP): from rabbit, polyclonal (DAKO) 
Anti-growth-associated protein-43 (anti-GAP-43): from rabbit, polyclonal (Abcam) 
Anti-ionized calcium binding adapter molecule 1 (anti-Iba1): from rabbit, polyclonal (Wako) 
Anti-NeuN: from mouse, monoclonal (Millipore) 
Anti-Rho kinase2 (anti-ROCK2): from goat, polyclonal (Santa Cruz) 
Anti-synaptophysin: from rabbit, polyclonal (Merck Millipore); from guinea pig, polyclonal 
(Synaptic Systems) 
Anti-synaptotagmin1 (anti-syt1) Atto647N-labeled: from mouse, monoclonal (Synaptic 
Systems) 
Anti-synaptotagmin1 -CypHer5E-labeled (CypHer): from mouse, monoclonal (Synaptic 
Systems) 
Anti-tyrosine hydroxylase (anti-TH): from rabbit, polyclonal (Zytomed); from mouse, 
monoclonal (Sigma Aldrich); from goat, polyclonal (Abcam) 
 
Secondary antibodies: 
Anti-guinea pig Alexa 488: from donkey (Dianova) 
Anti-mouse Cy2: from donkey (Dianova) 
Anti-rabbit biotinylated: from goat (Dianova) 
Anti-rabbit Dylight 488: from donkey (Dianova) 
Anti-rabbit Alexa Fluor 488: from donkey (Dianova) 
Anti-rabbit Cy3: from goat (Dianova) 
Anti-rabbit Cy3: from donkey (Dianova) 
Anti-rabbit Cy5: from goat, (Jackson ImmunoResearch Laboratory Inc.) 
Anti-rabbit horse raddish peroxidase (HRP): from goat (Cell Signalling Technologies) 
 
 





385 Stimulus Isolator (World Precision Intruments) 
96 well micro test plate (Sarstedt) 
12 well plate (Sarstedt) 
A310 Accupulser Stimulator (World Precision Intruments) 
Animal cages (IVC, Tecniplast) 
Axioplan microscope equipped with a 16-bit grayscale CCD camera (Carl Zeiss Microimaging) 
Axioplan microscope equipeed with MBF Q-imagin camera (Carl Zeiss Microimaging, MBF) 
Bead mill homogenizer, Precellys 24® (Precellys by Peqlab) 
Cage incubator (Okolab) 
Catwalk XT gait analysis system (Noldus) 
Camera Legria, HFM36 (Canon) 
Ceramin beads 1.4 mm (Precellys by Peqlab) 
Coulochem II electrochemical detector (ESA) 
Cover slides 24x60 mm (Menzel) 
Cryostat, CM 3050S (Leica) 
Cryomatrix (Thermo Scientific) 
Curix 60 Developer (Agfa) 
Eclipse Ti-E microscope equipped with a HBO-100W Lamp and an IXON X3897 Andor Camera 
(Nikon Instruments) 
Electrophoresis chamber (Bio-RAD) 
Electrophoresis power supply (GE Healthcare) 
Glass plates/Short plates (Bio-RAD) 
Glass capillaries (World Precision Intruments) 
Guard cell (ESA) 
Menzelglass cover slides, diameter 18 mm (Menzel) 
Micro4-based controller (World Precision Intruments) 
Micro-centrifuge, 5415R (Eppendorf) 
Micro injector, Nanoliter 2000 pump head (World Precision Intruments) 
Mini-driller equipped with a 0.8 mm drill head (Dremel) 
Mini Trans-Blot Cell setup (Bio-RAD) 
Mouse jaw holder (David Kopf Instruments) 




Nitrocellulose transfer membrane (Applichem) 
Rotarod for mice, model 47600 (UgoBasile) 
Rotor type 45Ti (Beckman Coulter Inc.) 
Sorvall Ultracentrifuge, Discovery 90SE (Hitachi GmbH) 
Spacer plates (Bio-RAD) 
Stereotactical frame (David Kopf Instruments) 
SuperFrost Plus Microscope Slides 25x75 x 1.0 mm (Menzel) 
TCS SP5 confocal microscope (Leica) 
TCS SPE confocal microscope (Leica) 
Wallac 1450 Micro beta TriLux-Luminometer (GMI) 
Whatman gel blotting paper (GE Healthcare) 
 
2.1.5. Animals  
Male C57Bl/6 mice (Charles River) 
Postnatal wistar rats (Central Animal Facility of the UMG) 
 
2.1.6. Software 
AxioVision 4.6 (Carl Zeiss Microimaging) 
CatWalk XT 10.0 (Noldus) 
CorelDRAW X3 (Corel Corporation) 
Cromeleon Chromatography Data System (Dionex. By Thermo Fisher Scientific GmbH) 
GraphPad Prism Demo (GraphPad Software Inc.) 
ImageJ 1.47v (N.I.H.) 
KyPlot 2.0 (KyensLab Incorporated) 
LAS AF 2.4.1 (Leica) 
MATLAB 7.5 (The MathWorks Inc.) 
Sigma plot 10.0 (Systat Software GmbH) 
Stereo Investigator9.0 (Micro Bright Field Inc) 
 




2.1.7. Buffers and solutions 
Blocking and antibody solution for ICC: 2.5% BSA, 0.1% TritonX 100 in PBS 
Blocking and antibody solution for IHC: 2.5% DS, 1% immunoglobulin free BSA, 0.1% TritonX 
100 in PBS 
Borate buffer: 100 mM; solution1: 19.7 g Na2B4O7 *10 H2O in 500 ml distilled H2O; solution2: 
3.09 g H3BO3 in 500 ml distilled H2O; adjust the pH of solution 2 with adequate 
amount of solution 1 to achieve a pH of 8.5. 
DAPI solution: 1µg/ml DAPI in PBS 
ECL-1: 10 µl/ml 250 mM luminol, 4.4 µl/ml 90 mM p-cumaric acid, 100 µl/ml 1M Tris pH 8.5 
in distilled H2O  
ECL-2: 0.9 µl/ml 30% H2O2, 100 µl 1M Tris pH 8.5 in distilled H2O 
Enzyme solution: 0.2 mg/ml cysteine, 2.0-2.5 units of papain suspension/ml, 1 mM CaCl2, 
500 µM EDTA in DMEM 
5-Fluoro-2´-desoxyuridine stock solution: 8.1 mM 5-Fluoro-2´-desoxyuridine, 20.4 mM 
uridine in DMEM 
Gelelectrophoresis buffer: 192 mM Glycine, 0.1% SDS, 25 mM Tris- HCl, pH 8.3 
High salt PBS: 500 mM NaCl, 20 mM Na2HPO4, pH 7.4 
HPLC buffer: 6.973 g/L NaO2C2H3, 7.365 g/L C6H8O7 *H2O, 0.105 g/L sodium octasulfonic acid, 
0.048 g EDTA  pH 4.3 using 1 M C6H8O7, 105 ml/L CH4O in 800 ml HPLC water 
Inactivating solution: 2.5 mg/ml BSA, 2.5mg/ml trypsin inhibitor, 10% FCS, in Neurobasal 
medium 
Mowiol: 6 g Glycerin, 2.4 g mowiol, 6 ml H2O, 12 ml 0.2 M Tris pH 7.2 
Neurobasal medium: 0.2% B27-supplement, 2 mM GlutaMAX, 1% pen/strep in Neurobalsal-A 
medium 
PBS: 9.5 mg/ml PBS in distilled H2O 
PFA solution (4%): 40 mg/ml PFA, 9.5 mg/ml PBS, 1-3 drops 1 M NaOH in distilled H2O 
Plating medium: 10% HS, 1% glutamine, 0.6 mg/ml glucose, in MEM 
Running phase gel: 4.2 ml 30% acrylamid bisacryl, 2.125 ml 4x Tris pH 8.8, 2.125 ml destilled 
H2O, 4.25 µl TEMED, 42.5 µl 10% APS 
Stacking phase gel: 0.65 ml 30% acrylamid bisacryl, 1.25 ml 4x Tris pH 6.8, 3.05 ml destilled 
H2O, 5 µl TEMED, 25 µl 10% APS 
TBS: 10 mM Tris HCL, 150 mM NaCl in destilled water     




TBS-T: 0.1% Tween20 in TBS, pH 7.6 
Transfer buffer: 192 mM Glycine, 20% Methanol, 25 mM Tris-HCl, pH 8.3 
Tris: 10 mM Tris-buffered saline pH 8.0 
Tyrode buffer: 124 mM NaCl, 5 mM KCl, 30 mM Glucose, 25 mM HEPES in distilled H2O, pH 
7.4, afterwards: 1 mM MgCl2, 2 mM CaCl2 
Washing solution for ICC: 2.5% BSA in PBS 
 
2.2. Methods 
2.2.1. Human postmortem tissue 
2.2.1.1. Characterization 
Human brain tissue for immunohistochemistry was obtained from the Department of 
Neuropathology and Prion Research of the Ludwig-Maximilians-University in Munich. 
Neuropathological diagnosis was based on the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD), the formation of neurofibrillary tangles (NFT) and Lewy body 
(LB) staging (McKeith et al., 2005; Heiko Braak et al., 2003). Brains arrived as formalin-fixed, 
paraffin–embedded 4 µm sections placed on glass slides.  
Brain sections from 7 Parkinson’s disease patients (PD) (between 69 and 80 years old, 
average age 75.7 +/− 4.2 years, 3 females and 4 males), 6 age-matched control subjects 
(amc) (between 67 and 87 years old, average age 78.3 +/− 8.5, 2 females and 4 males) and 5 
young control subjects (yc) (between 47 and 60 years old, average age 55.4 +/− 5.2 years, 5 
males) were examined. From all individuals unilateral sections from the region of the 
midbrain containing the substantia nigra (SN) and the putaminal striatum (PU) were 
available. In two subjects there was no area of putamen available and therefore only the 
striatal caudate nucleus (NC) was included into the analysis. Patient case and tissue details 










Table 2.1: Summary of patient cases investigated. Abbreviations: amc = age-matched control; LBs = Lewy 
bodies; ncl. = nucleus; NNP = no neuropathology; PD = Parkinson´s disease; PMI = post-mortem interval; SN = 
substantia nigra; yc = young control. 
Case 






midbrain sample striatum 
                  
1 yc 58 male NNP no 8 SN putamen 
2 yc 60 male NNP no 11 SN putamen 
3 yc 58 male NNP no >24 SN putamen 
4 yc 54 male NNP no 9.5 SN putamen 
5 yc 47 male NNP no na SN putamen 
6 amc 86 female NNP no 20 SN caudate ncl. 
7 amc 71 male NNP no 23 SN putamen 
8 amc 75 male NNP no 27 SN        caudate ncl. 
9 amc 67 male NNP no na SN putamen 
10 amc 87 male NNP no 48 SN putamen 
11 amc 84 female NNP no 22 SN putamen 
12 PD 71 male PD brainstem 60 SN putamen 
13 PD 77 female PD brainstem na SN putamen 
14 PD 77 male PD brainstem na SN putamen 
15 PD 80 female PD-dementia neocortical na SN putamen 
16 PD 76 male PD-dementia neocortical na SN putamen 
17 PD 69 female PD neocortical >48 SN putamen 
18 PD 80 male DLB neocortical 6 SN putamen 
 
2.2.1.2. Immunohistochemistry 
a) Fluorescence immunostaining 
Single- or multi-fluorescent immunostainings were all performed according to the 
same protocol: 
Paraffin-embedded sections were de-paraffinized for two times 10 min in xylene and 
rehydrated in ethanol solutions of decreasing concentration: 100% ethanol for 5 min, 
followed by 99%, 96%, 90%, 70% and 50% ethanol, each incubated for 5 min and stored in 
distilled water until next steps. 
For antigen retrieval, slides were incubated in 50 mM glycine (pH 3.5) for 25 min at 
90°C in water bath. After 1h of cooling at room temperature (RT), sections were treated with 
sudan black B (0.3% in 70% ethanol) for 5 min at RT to eliminate auto-fluorescence from 
lipids, rinsed 2 times for 5 min with PBS, followed by blocking and permeabilisation with 5% 
normal donkey serum (NDS), 1% free bovine serum albumin (BSA, immunoglobulin and 
protease free) and 0.1% tritonX-100 in PBS for 1h at RT. Immediately after blocking, 




incubation with primary antibodies was performed for single and co-stainings for 48 h at 4°C 
in 2.5% NDS in PBS. The following antibodies were used: anti-tyrosine hydroxylase (anti-TH, 
rabbit, 1:1000; anti-TH, mouse, 1:500; anti-TH, goat, 1:500) anti-ROCK2 (goat, 1:50), anti-
GAP-43 (rabbit, 1:300), anti-synaptophysin (rabbit, 1:100), anti-glial fibrillary acidic protein 
(anti-GFAP, rabbit, 1:300), anti-ionized calcium binding adapter molecule1 (anti-Iba1, rabbit, 
1:300) and anti-CD68 (ED1, mouse, 1:50). Before incubation with the ED1 antibody, sections 
were pre-treated with 0.05% trypsin in PBS for 20 min at 37°C to achieve optimal antigen 
retrieval.  
After incubation with primary antibodies, sections were rinsed 3 times for 5 min with 
PBS. Afterwards, all primary antibodies were detected by incubation with the appropriate 
species detecting secondary antibody for 1h at RT. Fluorophore-conjugated secondary 
antibodies used were DyLight 488, Alexa Fluor 488, Cy2, Cy3 or Cy5 (all 1:250), respectively. 
For co-stainings the sections were incubated with the particular primary or secondary 
antibodies simultaneously. After additional rinsing with PBS, nuclei were stained with 
4,6-diamidino-2-phenylindole (DAPI), rinsed again 3 times for 10 min and mounted with 
Mowiol®. Negative control staining was performed without incubation in primary antibodies 
asserting the appropriate detection of the secondary antibodies. 
 
b) Light stable immunostaining with 3,3´- diaminobenzidine (DAB) 
For counting of TH-immunoreactive (TH-IR) cells in the SNpc and to investigate the TH-IR 
fiber density in the striatum, slides were de-paraffinized as described above (see 2.2.1.2), 
endogenous peroxidases were blocked for 3 min with 3% H2O2 and rinsed 2 times for 5 min 
with Tris-base-saline (TBS). Sections were incubated with anti-TH antibody (from mouse, 
1:70) for 48h at 4°C followed by rinsing 3 times for 5 min with TBS. Treatment with a 
secondary biotinylated anti-rabbit antibody (1:200), at RT for 2h followed. After washing 
again 3 times for 5 min in TBS, incubation with VECTASTAIN ABC Peroxidase standard Kit (PK-
4000) for 2h at RT was performed to enhance detection signal. Finally sections were stained 
with DAB (DAB peroxidase substrate Kit) for 15 min and mounted with DPX. 
 




2.2.1.3. Stereological quantification of substantia nigra dopaminergic neurons and 
evaluation of the striatal dopaminergic fiber density in human brain sections 
The number of TH-IR neurons in the human substantia nigra (SN) was assessed 
unilaterally using stereological methodology. One section through the SN was analyzed per 
case using Stereo Investigator software and a Zeiss microscope. The area of the SN was 
manually outlined using a 2.5x objective and a point grid was overlaid onto each section 
constituting areas of the counting frames (counting frame 500x500 µm). Immunostained 
cells were counted by the optical fractionator method (10x objective) and the total number 
of TH-IR cells in the unilateral SN was estimated per slice by the software. Stereological 
counts were performed by a blinded investigator.  
To analyze the TH-IR fiber density, sections were acquired with a 10x objective using 
the Stereo Investigator software which assembles single acquired images into one picture via 
the Virtual Slice® module. TH-IR was detected by measuring the mean grey value using the 
ImageJ software. 
 
2.2.1.4. Image acquisition and analysis of protein expression in the human SNpc 
and striatum 
Brain sections were imaged with a Zeiss Axioplan microscope equipped with a 16-bit 
grayscale CCD camera and AxioVision software using a 63x objective. Micrographs were 
taken at 15-20 randomly chosen visual fields per SNpc or putamen (caudate nucleus 
respectively), containing TH-IR cells or striatal neuropil. For detailed analysis of the 
fluorescent signal of ROCK2, GAP-43 or synaptophysin staining, an appropriate area of the 
TH-IR soma or TH-IR neurite, as well as of the adjacent neuropil was chosen to measure the 
mean grey value of the respective immunofluorescence using the freehand selection from 
ImageJ (see Figure 2.1).  




                         
Figure 2.1: Illustration of method to measure immunofluorescence in certain areas of the midbrain. 
Dopaminergic cells (DAergic) were identified by TH staining and intracellular measurement was performed in 
areas (red) not containing neuromelanin (NM) or the nucleus (ncl). For evaluation of immunoreactivity in the 
neuropil, a randomly chosen area was analyzed (red circle), containing no TH-IR structures or other nuclei. 
 
To allocate enhanced ROCK2 expression to specific cell types, 20 images (98.41x 
98.41 µm) from the SNpc or the striatum, respectively, were acquired randomly using Leica 
Microsystems TCS SP5 confocal microscope with a 63x oil immersion objective (kindly 
provided by the Max-Planck-Institute for biophysical chemistry, Göttingen) in order to 
correlate ROCK2-IR to astrocytes or to Iba1-IR microglia. Therefore co-labeled GFAP- and 
ROCK2-, or Iba1- and ROCK2-IR cells were quantified using ImageJ cell counter plugin. 
In order to distinguish between phagocytic active and resting ROCK2-positive 
microglia the number of ED1-/ROCK2 co-labeled cells was quantified with ImageJ cell 
counter plugin on 5 randomly chosen micrographs (400 x 530 µm) taken with the AxioVision 
4.6 MosaiX module with a 63x objective.  
 
2.2.2. The 6-OHDA mouse model of PD and intracranial injection of AAV.shRNA 
As animal model for PD we chose the 6-OHDA mouse model, because it addresses 
best the focus of our interests in order to mimic the nigrostriatal neurodegeneration in PD. A 
unilateral injection of the neurotoxin 6-OHDA was applied in the striatal putamen and 
simultaneously the shRNA containing vector was injected into the ipsilateral SN using a 
stereotactical frame.  




2.2.2.1. Animals  
The surgeries of mice were performed under the grant approval 11-0554 and were 
carried out regarding to the regulations of the local animal research council and legislation of 
the State of Lower Saxony (Braunschweig, Germany). 
For the experiments, 8 weeks old male C57Bl/6 mice were housed in groups of five in 
individually ventilated cages under a 12h light/12h dark cycle with free access to food and 
water. Mice were pre-treated with metamizol (1.5 mg/ml) in drinking water 3 days prior to 
the surgeries to achieve optimal analgesic conditions during and after the operation.  
 
2.2.2.2. Virus  
The viruses were kindly provided by Prof. Dr. Uwe Michel and Dr. Jan C. Koch (both 
Department of Neurology, UMG) and have been produced as described before (Koch et al., 
2014; Michel et al., 2005). Shortly, adeno-associated viral vectors (AAV) co-expressing a 
short-hairpin RNA (shRNA) under the control of the H1-promoter and the fluorophore dsRed 
under the control of the neuron-specific human synapsin promoter were produced. The 
sequences of the shRNA primers were as follows (in bold: sequence of the respective siRNA-
sense and -antisense strand, in italics: sequence of the hairpin turn): 








The vectors used for virus production were pAAV-9(5)hSyn-DsRed-H1-ROCK2-shRNA 
containing the H1 promotor for the shRNA and the hSyn promoter for the fluorophore dsRed 
(Figure 2.2-A). The respective control vector, expressing an shRNA against EGFP and the 
fluorophore dsRed was pAAV-9(5)hSyn-DsRed-H1-EGFP-shRNA (Figure 2.2-B). For in vivo 
experiments, the virus production was performed using the serotype AAV2 as it is best 




established for this paradigm, targeting primarily neurons (Löw & Aebischer, 2012; 
Tenenbaum, 2004). 
 
2.2.2.3. Surgery preparations/equipment 
Stereotactic injections of 6-OHDA were performed according to the protocol of 
(Alvarez-Fischer et al., 2008; Tatenhorst et al., 2014)). In detail, before starting the surgery, 
the micro injector was prepared by filling a self-pulled glass capillary with around 3 µl 
mineral oil, connecting it to the micro injector and withdrawing a 500 nl air bubble to 
achieve separation of oil and substance to inject. 4 µg of 6-OHDA were freshly dissolved in a 
volume of 2 µl 0.2% L-ascorbic acid (L-AA) in PBS and the 6-OHDA substance or the virus 
solution, respectively, was withdrawn into the capillary in amounts of 1.5-2.5 µl of substance 
with the help of a micro4-based controller. 
 
2.2.2.4. Injection of 6-OHDA and the AAV.shRNA 
Mice were anesthetized by a mixture of ketamine (200 mg/kg bodyweight) and 
xylazine (10 mg/kg body weight) in Sterofundin® (infusion solution). Eyes were protected 
with eye ointment (bepanthene) and mice were head fixed by ear bars and jaw holder in a 
stereotaxic frame (Figure 2.2-C). The skin covering the skull was disinfected and cut with a 
scalpel through the midline, starting between the eyes until the occipital bone exposing 
bregma and lambda. The skin was moved to the sites by small hooks and bregma was 
calibrated. With a mini-driller equipped with a 0.8 mm drill head two minimal trepanations 
at the positions of the coordinates for the right striatum (coordinates relative to Bregma: 
anterior-posterior (AP) +0.04 cm; medio-lateral (ML) -0.18 cm; dorso-ventral (DV) -0.35 cm, 
Figure 2.2-D) and the ipsilateral SN (coordinates relative to Bregma: AP -0.29 cm, ML -0.12 
cm, DV -0.45 cm, Figure 2.2-E) accordingto the mouse brain atlas (Paxinos & Watson, 2001) 
and the coordinates from Alvarez-Fisher and colleagues (2008) were performed. The 
capillary was moved to the particular depth and the respective substance was injected in a 
rate of 0.5 µl/min (Figure 2.2-C). Afterwards the needle was left in place for 5 min before 
retraction to prevent reflux via the injection tract.  




After removing the injection capillary, mice were unhinged from the stereotactic 
frame and the skin lesion was closed with 10 µl of histoacrylic glue. Subcutaneous injection 
of 1 ml pre-warmed Sterofundin® was administered and mice were warmed with a 37°C 
heating pad until they woke up. In the following days mice were treated with metamizol 
(minimum 3 consecutive days), fed with mashed food and monitored for vitality. 
 
 
Figure 2.2: Illustration of the striatal 6-OHDA mouse model of PD and treatment with ROCK-shRNA into the 
SNpc. The vector map of the H1-controled AAV.ROCK2-shRNA is shown in A and the respective control map, 
expressing a shRNA against EGFP, is depicted in B. Mice (1) are head-fixed with ear bars (3) and a jaw holder (4) 
in a stereotaxic frame. The glass capillary (2) is moved down to the respective position to inject the substance. 
D and E are illustrating the sections from the coordinates of the putaminal striatum (yellow area in D) and the 
midbrain with the SNpc (yellow area in E) both from Paxinos & Watson mouse brain atlas (Paxinos and Watson, 
2001). 
 
2.2.2.5. Animal group classification 
All animals received intracranial injections of 2 µl substance (either 6-OHDA or the 
vehicle L-AA) into the right striatum and simultaneously 1 µl substance (either AAV.shRNA or 
the vehicle PBS) into the ipsilateral SN. In order to achieve optimal effects of shRNA 
mediated ROCK2 downregulation in dopaminergic SN neurons, two different virus titers 
were employed: One group of animals was injected with a high virus titer of 1.0x 108 
transforming units (TU) in 1 µl PBS (in the following named as 6-OHDA/ROCK2-shRNA1.0) 
and the second group received AAV in a titer of 0.25x 108 TU/µl (named as 6-OHDA/ROCK2-
shRNA0.25). Vehicle control groups were treated with 2 µl of 0.2% L-AA into the striatum 
and 1 µl PBS into the ipsilateral SN (named as LAA/PBS). Lesion control animals were injected 
with 2 µl 6-OHDA into the right striatum and 1 µl PBS into the SN (named as 6-OHDA/PBS). 




Virus control animals received injections of 2 µl 6-OHDA into striatum and 1 µl 
AAV.dsRed.EGFP-shRNA in the high titer of 1.0x 108 TU/µl into the SN (named as 
6-OHDA/control-shRNA). Both AAV.ROCK2-shRNA groups were injected with 1 µl of the virus 
solution into the SN and simultaneously with 2 µl 6-OHDA into the ipsilateral striatum. 
 
2.2.2.6. Behavior analyses  
To assess motor behavior, four different tests, the apomorphine turning test, the rotarod 
assessment, the cylinder rearing test and the Catwalk XT gait analysis, were performed two 
and four weeks after lesion. The animal numbers in the respective test and respective time 
point are summarized in table 2.2. 
 
Table 2.2: Number of animals tested in motor performance at two different time points.  






 LAA/PBS 10 10 10 10 
2 weeks 6-OHDA/PBS 8 10 10 10 
after  6-OHDA/control-shRNA 10 10 10 10 
injections 6-OHDA/ROCK2-shRNA0.25 12 12 12 12 
 6-OHDA/ROCK2-shRNA1.0 11 11 11 11 
 LAA/PBS 10 10 10 10 
4 weeks 6-OHDA/PBS 8 8 8 8 
after  6-OHDA/control-shRNA 10 10 10 10 
injections 6-OHDA/ROCK2-shRNA0.25 12 12 12 12 
 6-OHDA/ROCK2-shRNA1.0 11 11 11 11 
 
a) The apomorphine turning test 
This behavioural test was applied to monitor the efficacy of the unilateral 6-OHDA 
lesion in the treatment groups and to determine potential recovery effects in turning 
behaviour after AAV.ROCK2-shRNA treatment. Application of the dopamine agonist 
apomorphine results in a rotation of mice to the contralateral (ctl) side induced by a 
hyperstimulation of compensatory upregulated D2-receptors on striatal postsynapses 
(Ungerstedt, 1971). Mice received a subcutaneous injection of apomorphine 0.5 mg/kg body 
weight in 0.9% saline, were placed in round arena of 20 cm in diameter and turning 
behaviour was monitored ten minutes after injection for 20 min by videotaping with a video 




camera from above. The test was performed at two and four weeks after 6-OHDA 
lesion/virus injection and total turns to the ctl as well as to the ipsilateral (ipl) side were 
counted manually.  
 
b) The cylinder rearing test 
The cylinder rearing test was employed to use natural mice exploration activity to 
assess potential unilateral unbalance in dopamine levels in the brain which may result in 
unequal forelimb usage after 6-OHDA lesion. Each mouse was placed into a plexiglass 
cylinder of 25 cm in height and 11.5 cm in diameter (Figure 2.3-A). During the test the 
explorative behaviour was videotaped from the front and forelimb use of the first contact 
against the glass wall while rearing was recorded for 5 min. A 90 degrees angulated mirror 
was arranged behind the cylinder to enable observation of forelimb usage even if the mouse 
turned away from the camera (Figure 2.3-A). Rating criteria were “right” and “left” when the 
animal used the respective forelimb singly to touch the cylinder during a rear, “both” when 
the animal used both left and right forelimb simultaneously to touch the cylinder during a 
rear or “free” when the animal reared up the body without touching the cylinder wall. 
Recorded movies were manually analyzed. Statistical analysis pictured the percentage of 
“both”, “right”, left” or “free” movements of all movements recorded during observation 
time.  
 
c) Rotarod performance test 
The rotarod test was performed at two and four weeks after cerebral injections. Mice 
were placed on the rotarod and were forced to motor activity by the rotating rod spinning 
with an accelerating speed (5 to 40 rpm within 5 min). The rod featured 5 separated sites 
rendering the possibility to let 5 mice perform the test simultaneously (Figure 2.3-B). Each 
trial stopped when a mouse fell down and thereby activated a lever, which automatically 
stopped the time, or when 5 min motor performance was completed. All mice were pre-
trained three times on the rotarod on every second day before cerebral injections. The final 
test was performed in three sessions with an intertrial interval of 30 min to avoid stress and 




prostration. Each motor performance was quantified by measuring the time mice stayed on 
the rod and the average value was compared between the groups. 
 
d) Catwalk gait analysis 
To monitor changes in gait performance of mice injected with 6-OHDA and the 
AAV.shRNA, the Catwalk XT gait analysis system was used. Animals were placed on a glass 
plate walkway of 4 cm width and videotaped from below with a high speed digital camera, 
connected to a computer equipped with the Catwalk software (Figure 2.3-C). The 
combination of a red illuminated ceiling and the green illuminated glass plate enable the 
software to automatically detect the animal paw or body prints on the glass plate. 
Detection settings to achieve optimal distinction between paw prints (Figure 2.3-D) 
and background noise were chosen as follows: camera gain 24.41, intensity threshold 0.27 
and maximal allowed speed variation of an animal during one run was set to 60%. Three 
compliant runs per animal were recorded, parameters for each single paw print (Figure 
2.3-E) were evaluated and the means for different parameters were compared between the 
groups.  




                 
 
Figure 2.3: Overview of the experimental setup for behavioural motor tests. The cylinder rearing test is 
illustrated in A. Mice could be observed during rearing from all sides with the help of a mirror, which was 
arranged behind the cylinder. The rotarod test (B) allows the observation of motor endurance of 5 mice 
simultaneously running on the rod. Subtle motor changes could be precisely measured with the Catwalk gait 
analysis (C-E). The hardware compounds are depicted in C from the front (left image) and from the side (right 
image) with 1: red illuminated ceiling, 2: corridor walls, 3: green illuminated glass walkway, 4: camera position 
and 5: the walkway tunnel. In D a single frame of the recordings is illustrated, showing a mouse running 
through the walkway. The footprints are detected by the camera and classified for the whole run as LH: left 








2.2.2.7. Animal euthanasia and tissue processing 
Four weeks after the 6-OHDA lesion and the injection of viral vectors animals were 
sacrificed and either perfused for immunohistochemistry (IHC) or brains were freshly 
prepared for neurochemical analysis. 
 
2.2.2.7.1. Transcardial perfusion  
For immunohistochemical investigations of protein expression levels, the transcardial 
perfusion method was performed to clear the vasculature from blood, fix the ultra-structure 
of the tissue and preserve protein conformation. Animals were deeply anaesthetized with 
CO2 inhalation, supinely fixed on a rack and the abdominal cavity was opened. The 
diaphragm was carefully intersected and the ribs were bilaterally cut to open the thorax. The 
pericardium was removed and the still beating heart was perforated in the left ventricle with 
a cannula connected with a tube to a syringe filled with ice-cold PBS. By increasing pressure 
from the syringe, the PBS was forced to enter the ventricle and further into the aorta. 
Setting a small cut in the right atrium allowed the blood to be voided and enabled the PBS to 
perfuse the whole body including the brain. Successful blood cleaning was indicated by 
colour changing of the liver from red to yellow. After perfusion of approximately 50 ml of 
ice-cold PBS, the fluid was replaced with 50 ml of 4% paraformaldehyde (PFA) in PBS. The 
brain was removed and post-fixed in 4% PFA for two days, then transferred into 30% sucrose 
in PBS for three days to dehydrate the tissue. Brains were frozen at -80°C until 
cryosectioning.    
 
2.2.2.7.2. Cryosectioning and IHC of mouse brains 
The still frozen mouse brains were embedded into cryomatrix and the region of the 
striatum (Bregma AP +1.18 to -0.70) and the midbrain containing the area of the SN (Bregma 
AP -2.18 to -4.04 mm) were coronally cryosectioned using a Leica cryostat resulting in 30 µm 
sections and stored in 0.1% sodium azide/PBS at 4°C until staining.  
For evaluation of dopaminergic cell numbers in the SN, every fourth section was 
stained using a free-floating method. After rinsing the sections 3 times for 5 min with Tris-
buffered saline (TBS) endogenous peroxidases were quenched by incubating sections in 40% 




methanol and 1% H2O2 in TBS for 15 min. After washing again in TBS unspecific antibody 
binding was blocked by 5% NGS in TBS for 1h at RT. Incubation with an anti-TH primary 
antibody (anti-TH, rabbit) diluted in 2% NGS/TBS was performed for 48h at 4°C. 
After washing 3 times for 5 min in TBS, sections were treated with a secondary 
biotinylated anti-rabbit antibody in TBS at RT for 2h. Incubation with VECTASTAIN ABC 
Peroxidase standard Kit for 2h at RT was performed to enhance signal detection. Finally, 
sections were rinsed again 3 times for 5 min in TBS and visualized with the chromogen DAB 
(DAB peroxidase substrate Kit) for 5 min. The staining reaction was stopped with distilled 
H2O and sections were collected on SuperFrost Plus microscope slides. After drying for 
around 3-5 days at RT, a Nissl staining was performed as follows: sections were rehydrated 
for 5 min in distilled H2O and incubated in 1% thionine acetate for 7 min. After rinsing the 
slides again in distilled H2O for 2 min, dehydration of the tissue was performed by incubation 
in ascending alcoholic solutions of 70%, 90%, 95% ethanol each for 2 minutes, followed by 5 
min in 100% isopropanol and subsequent incubation in xylene 3 times for 5 min. Finally, 
moist sections were mounted with DPX. 
For striatal TH-density analysis, every fourth section was collected on microscope 
slides and stained according to the same protocol described above (see nigral TH-IHC), but 
the antibody solutions were put on the top of the slide. The DAB staining was performed 
with the Elite ABC Kit with nickel intensification and sections were mounted with DPX 
without Nissl staining. 
To demonstrate the cell type specificity of the synapsin-promoter-driven dsRed 
expression, nigral sections were stained with the free floating method as follows: sections 
were rinsed 3 times for 5 min with PBS and blocked with 5% NGS in 0.1% PBS-TritonX-100 for 
30 minutes at RT. Subsequently, samples were incubated with anti-neuronal nuclei (NeuN) 
(1:1000), anti-GFAP (1:500) or anti-Iba1 antibody (1:500) for 24h at 4°C. After 3 rinses in PBS 
for 5 min, sections were incubated with Cy2-conjugated antibody (1:250) for 1h at RT. 
Finally, sections were DAPI stained and mounted with Mowiol®. 
 
 




2.2.2.7.3. Neurochemical analysis of dopamine and dopamine metabolites in the 
striatum of 6-OHDA lesioned in mice 
To specify the functional impairment of dopaminergic terminals and synapses in the 
striatum at four weeks after the 6-OHDA intoxication, one cohort of mice was sacrificed by 
cervical dislocation, to ensure immediate processing of brain tissue without anaesthetic 
additives. The brain was removed from the skull and cut along the midline resulting in two 
hemispheres. The right striatum was dissected on ice, transferred into cryovials (micro tube 
2 ml), which were previously filled with 0.6-0.8 g of Precellys sceramin beads 1.4 mm and 
snap frozen with liquid nitrogen until further processing. To degrade enzymatic action 50 μl 
of 0.1 M HClO4 per mg of striatal tissue were added and samples were homogenized with a 
bead mill homogenizer. Subsequently vials were centrifuged in a microcentrifuge at 10,000 
rounds per minute (~9300 g) for 5 min, supernatant was transferred into a new reaction 
tube and again centrifuged at 13,000 rpm for 10 min at 4°C. To measure the amount of 
dopamine (DA), homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) 50 µl 
of supernatant were transferred into HPLC vials. 
The HPLC system was composed of a Guard cell, which was kept at 600 mV to oxidize 
impurities in the eluent, a C18 reverse-phase HR-80 catecholamine column for 
catecholamine extraction and an ESA Coulochem II electrochemical detector equipped with 
a 5011A analytic model detector (E1 = 50 mV, E2 = 400 mV). For measurements, the samples 
were loaded to the HPLC autosampler, which was cooled down before to 6°C and the system 
injected 20 µl of each sample to the column. The mobile phase (HPLC buffer, filtered and 
degased) was running with a flow rate of 0.4 ml/min. The HPLC buffer prevented changes in 
pH during the mobile phase, which could affect the retention time of the analysed molecules 
and result in changes in the chromatogram. To accurately determine catecholamine 
amounts, dopamine, HVA and DOPAC standards were run every 15 samples. The standards 
were prepared from 10 µM stocks by dilution with 0.1 M HClO4 to 0.0, 0.15, 0.30 and 1.5 µM. 
Data collection and processing was done with a Chromeleon Chromatography Data System 
by integrating the areas under the specific peak curves. Data was displayed as ng per mg wet 
tissue. Groups analysed were as follows: LAA/PBS with n=10; 6-OHDA/PBS with n=8; 
6-OHDA/control-shRNA with n=10; 6-OHDA/ROCK2-shRNA0.25 with n=10 and 
6-OHDA/ROCK2-shRNA1.0 with n=11. 
 




2.2.2.8. Stereological quantification of SNpc neurons in mice 
The number of TH-positive neurons and Nissl positive cells in the SN was determined 
by stereological counting using Stereo Investigator software from DAB immunostained brain 
sections. Every 4th section through the SN was analyzed by two blinded investigators. At 2.5x 
objective magnification the SN was outlined manually and the TH-IR and Nissl-positive cells 
were counted at 40x objective magnification using the optical fractionator method: cells 
were identified in counting frames sized 50x50 µm and the total number of immunolabeled 
cells was calculated by the optical fractionator method for the whole unilateral SNpc per 
animal. The evaluation of Nissl cells was performed to confirm loss of neurons rather than 
mere down-regulation of TH-expression. Values represent averaged assessments in the 
ipsilateral SN of the hemisphere with dual intracerebral injections. Groups analyzed were as 
follows: LAA/PBS with n=4, 6-OHDA/PBS with n=7, 6-OHDA/control-shRNAwith n=5, 
6-OHDA/ROCK2-shRNA0.25 with n=4 and 6-OHDA/ROCK2shRNA1.0 with n=5 after four 
weeks. 
 
2.2.2.9. Striatal density measurement in mouse striata 
To assess the dopaminergic degeneration in the lesioned striatum, the TH-IR was 
measured four weeks after cerebral injections. Immunostained sections of each animal were 
acquired using the Virtual Slice module of Stereo Investigator software described above (see 
2.2.1.3.), the mean gray value of striatum and cortex were measured using ImageJ freehand 
selection, followed by image processing with background subtraction. Five sections per 
animal around the lesion site were analyzed and the mean TH-IR-signal was calculated in 
relation to the TH-signal of the contralateral striatum (lesioned hemisphere/unlesioned 
hemisphere in %). Groups included were as follows: LAA/PBS with n=5, 6-OHDA/PBS with 
n=7, 6-OHDA/control-shRNA with n=5, 6-OHDA/ROCK2-shRNA0.25 with n=4 and 








2.2.3. In vitro inhibition of ROCK2 in primary neuron cell culture 
Primary hippocampal cell cultures were employed to investigate synaptic vesicle 
dynamics under treatment of the ROCK2 inhibitor fasudil. To establish a mature neuronal 
network with numerous synaptic compositions, cells have to be cultured up to 12-14 days in 
vitro (DIV). To generate optimal physiological conditions for preserving the vitality of cells, it 
is important to coat the culture plates or coverslips with attachment factors and provide an 
adequately nutritive culture medium. Donor animals were supplied by the central animal 
facility of the UMG and experiments were performed in the European Neuroscience Institute 
(ENI) Göttingen in cooperation with Prof. Silvio Rizzoli. 
 
2.2.3.1. Coating of culture plates and preparation of coverslips 
For stimulation experiments, hippocampal neurons were cultured onto glass 
coverslips (diameter: 18mm), which first were cleaned by shaking in 200 mM HNO3 on a lab 
shaker over night (ON). Afterwards the coverslips were rinsed several times with distilled 
water and finally in 70% ethanol. Before being placed into 12 well-culture plates, the ethanol 
was flamed and all further procedures were performed under sterile conditions. For coating, 
the coverslips were transferred into the well plates and incubated with 1 ml 1mg/ml Poly-L-
lysine (PLL) per well in borate buffer ON in an incubator at 37°C with 5% CO2 and 95% 
humidity. After rinsing 4 times with sterile distilled water, 1ml plating medium was filled in 
each well and plates were kept in the incubator for 2 days. 
 
2.2.3.2. Tissue dissection 
To obtain primary hippocampal neurons, young Wistar rats (postnatal day 0-2) were 
killed by decapitation, the brains were exposed, the hippocampi from both hemispheres 
were dissected and the meninges were removed. The hippocampi were pooled together in 
ice-cold HBSS, transferred into the pre-warmed enzyme solution and kept slowly rotating at 
37°C for 60 min. Later, the enzyme solution was replaced by pre-warmed inactivating 
solution for 15 min and rinsed with pre-warmed Neurobasal medium. Using a handmade 
fire-polished Pasteur pipette, cells were gently triturated for dissociation in fresh Neurobasal 
medium, then counted with a Neubauer counting chamber and seeded in a density of 




around 50,000 - 100,000 cells/well into 1 ml plating medium. Neurons were kept in 
incubator at 37°C with 5% CO2 and 95% humidity for 1h and then the whole medium was 
replaced by 1.5 ml/well pre-warmed Neurobasal-culture medium. A partial Neurobasal 
medium change (500 µl) was performed on DIV1-2 and after 5 DIV 20 µl 5-Fluoro-2´-
deoxyuridine stock solution was added to each well to inhibit the proliferation of glia cells in 
culture. 
For western blotting, cells were seeded without coverslips into culture plates with a 
density of 500,000 cells/well. 
 
2.2.3.3. In vitro treatment with the ROCK2 inhibitor fasudil 
The concentration of 20 µM fasudil was chosen, because it had the most pronounced 
effect on neuronal survival and neurite outgrowth in primary dopaminergic midbrain 
cultures in previous studies (Tönges et al., 2011). Primary hippocampal neurons were 
treated with 20 µM fasudil at DIV10 by adding 20 µl of 1 mM fasudil solution into each well 
containing 1ml medium and gently mixed. On DIV12 the whole medium was replaced by 
fresh pre-warmed medium containing new 20 µM fasudil. Experiments were performed on 
DIV14-15. 
 
2.2.3.4. ToxilightTMcell toxicity assay 
To exclude toxic effects on the neurons after fasudil treatment, we used the 
ToxiLight™ non-destructive cytotoxicity Bio Assay Kit from Lonza. The Kit quantitatively 
measures the release of adenylate kinase (AK) from dying cells by adding the AK substrate 
ADP, which is converted by AK to ATP. Luminescence resulted from the reaction of ATP and 
luciferin, so that the emitted light is linearly related to AK concentration. For the ToxiLight™ 
assay, 100 µl of culture medium supernatant were collected from each well on DIV14-15 and 
50 µl were transferred in duplications into a 96 well plate. For background correction, fresh 
medium was measured in 2 wells. To each sample 50 µl of the AK detection reagent were 
added and the measurement was performed after 5 min incubation time. Luminescence was 
acquired by a Wallac TriLux-Luminometer, single values were averaged and the background 
was subtracted. Data was generated from 3 independent experiments. 




2.2.3.5. Electric cell stimulation 
To investigate the effects of long term ROCK2 inhibition on synaptic vesicle exo- and 
endocytosis, two experimental setups were used according to the protocols from Prof. Silvio 
Rizzoli (see also Wilhelm et al., 2010): in one approach the cells were fixed after the 
experiment to enable immunocytochemistry (ICC) and evaluation of stimulation-induced 
events, in particular by identifying synapses with co-staining of synaptophysin. In the other 
experiment, a life imaging depicted the vesicle dynamics during and directly after 
stimulation by real time acquisition. 
To perform experiments with fixable readout, coverslips with cultured neurons on 
the surface were gently rinsed in pre-warmed physiological tyrode buffer and placed into a 
custom-made platinum wire field stimulation chamber (Figure 2.4-A). To allow for antibody 
incorporation into presynapses, cells were incubated in pre-warmed tyrode buffer 
containing an anti-synaptotagmin1 (syt1) antibody conjugated with Atto®647N (1:100) for 30 
seconds and electrical field stimulation was applied through the platinum wires (8 mm 
distance) which reached into the antibody solution close to the cell surface. By strong 
stimulation of neurons with field pulses at 20 Hz for 30 s at 100 mA with a stimulus isolator 
and an Accupulser stimulator, at RT synaptic vesicles underwent membrane fusion and 
transmitter release. Thereby the intravesicular domain of the syt1 transmembrane protein 
was exposed to the extracellular antibody solution and provided thereby the antigen for the 
syt-antibody. During vesicle recycling and endocytosis, the fluorophore-conjugated 
syt-antibody is endocytosed into the neuron (Figure 2.4-B). To guarantee the uptake of all 
endocytosed vesicles, which underwent the transmitter release before, the coverslips were 
left in the antibody solution for 6 minutes from the start of stimulation. Afterwards, cells 
were rinsed in ice-cold tyrode buffer and fixed in 4% PFA in PBS on ice for 10 min and further 
30 min at RT. 
To generate a negative or unstimulated control, coverslips were incubated in ice-cold 
tyrode buffer containing the Atto®647N conjugated syt-antibody (1:100) and 3 µM 
tetrodotoxin (TTX) to selectively block voltage depended sodium channels and to minimize 
spontaneous action potentials. After rinsing cells again in ice-cold tyrode buffer, they were 
fixed as described above. 
For life imaging, incubation with syt1-CypHer5E-labeld antibody (1:100 in Neurobasal 
medium) was performed for 1-1.5 h at 37°C in an incubator. CypHer is a pH-sensitive cyanine 




dye that is maximally fluorescent at a pH of 5.5 and non-fluorescent at pH 7.4. During 
incubation, it is internalized into the neurons by endocytosis from spontaneous bursting 
activity of hippocampal neurons (Pimashkin et al., 2011), depicting the highest fluorescent 
signal from the luminal acidic milieu of vesicles. After rinsing the coverslips with pre-warmed 
tyrode buffer, they were fixed in the stimulation chamber covered with tyrode buffer and 
attached to an inverted Nikon Eclipse Ti-E microscope equipped with a plan 60x oil 
immersion objective and cage incubator system to maintain a constant temperature of 37°C 
and the CO2 level at 5%. The filter set used was: Cy5/CypHer ET/EX: 620/60. The acquisition 
was started once the stimulation chamber was placed into the microscope, recording images 
every two seconds with an exposure time of 200-300 ms. After 1 min acquisition of the 
resting state, neurons were stimulated with 20 Hz for 30 s at 100 mA and images were 
recorded up to 6 min to allow total recycling of exocytosed synaptic vesicles. 
 
                        
Figure 2.4: Experimental setup for in vitro cell stimulation. In A the stimulation chamber is pictured. In the 
middle of the chamber, the coverslip is placed and the platinum wires are fixed above. In B a scheme (modified 
from Wilhelm et al., 2010) of the antibody coupling procedure is illustrated: as reaction to a stimulus, vesicles 
fuse with the plasma membrane, thereby present the intraluminal antigene to the antibody solution and 
incorporate the antibody during endocytosis into the cell. 
 
2.2.3.6. Immunocytochemistry 
To identify synapses in culture, a co-staining with the synaptic marker synaptophysin 
was performed. After fixation, cells were shortly rinsed with PBS and incubated in 100 mM 
NH4Cl in PBS for 20 min at RT to quench free aldehydes from PFA. For blocking of unspecific 
bindings, coverslips were incubated with 2.5% BSA and 1% TritonX-100 3 times for 5 min on 
shaker at RT. Afterwards incubation with primary anti-synaptophysin (anti-synphy, 1:500) 
antibody in blocking solution was performed for 1h at RT and then rinsed 3 times for 5 min 




with blocking solution. Thereafter, the coverslips were incubated with secondary anti-guinea 
pig-Alexa Fluor488 antibody (1:200) in blocking solution for 1h at RT. Coverslips were 
washed with 2.5% BSA, followed by rinsing with a high salt PBS solution and finally with PBS, 
all 3 times for 5 min at RT. Coverslips were mounted with Mowiol and imaged with Leica 
Microsystems TCS SPE confocal microscope (kindly provided by the Max-Planck-Institute for 
biophysical chemistry, Göttingen) with a 100x oil immersion objective.  
 
2.2.3.7. Image processing and analysis of in vitro experiments 
To assess the amount of synaptophysin and syt1 co-localized synaptic boutons on 
fixed hippocampal neurons, all images were acquired with the same laser intensity and 
smart gain for all conditions at 15-20 randomly chosen visual fields from the coverslip.  
All image and data analysis for in vitro experiments were performed with custom-
written routines from Prof. Silvio Rizzoli using MATLAB 7.5. Confocal acquired images were 
exported into RAW data tiff.-files and processed by a MATLAB script, which subtracted the 
mean background of a defined area in each picture and calculated the number of 
co-localized pixels generated from syt1-Atto®647N- and synphy-immunostaining. The mean 
pixel values, representing the synaptic activity, were compared between the groups. 
Movies generated from life imaging were processed with ImageJ and the plugin 
“intensity vs. time monitor” to save the pixel information over time as txt.-files. MATLAB was 
programmed to calculate a bleaching correction for each movie to obtain only fluorescent 
shifts indicated by stimulation and changing of pH during endo- and exocytosis. 
Furthermore, the fluorescent information for each time frame from the movies was 
averaged to output one fluorescent value per time point resulting in 181 values depicting a 
curve of fluorescent change after stimulation. From this curve single vesicle kinetic events 
were investigated. The measured fluorescent signal decreased during exocytosis and 
increased during endocytosis due to the pH of the luminal milieu similar to exponential 
curves. Thus, with the help of Sigma Plot software, a computation of an exponential fit was 
performed that describes best the averaged curves per condition. The resulting curve 
relationships were best fitted with 3 parameter exponential decay (exocytosis) or 
exponential rise to maximum (endocytosis) functions. To calculate the vesicle kinetics the 
time constant τ was identified, which describes the time an exponential decay needs to 




reach around 36.8% (1/e) of the initial value. τ also describes the time an exponential rise 
needs to reach around 63.2% of the maximum value. Using these calculations, the vesicle 
kinetics for exocytosis and reuptake were compared between the control and the fasudil 
treated group and depicted as means per condition. 
 
2.2.3.8. Western blot analysis  
To assess molecular changes in the synaptic G- and F-actin ratio after fasudil 
treatment, a western blot analysis for G-actin protein amounts were performed by using a 
G-actin/F-actin in vivo assay kit that provided all needed solutions and antibodies to perform 
the cell lysis and western blotting according to manufacturer’s instructions. 
a) Cell harvesting 
For generating samples, medium was removed and pre-warmed LAS2 buffer 
(containing lysis and F-actin stabilization buffer, 100 mM ATP stock, 100 x protease inhibitor 
cocktail, all from actin/F-actin in vivo assay kit) was added to each well, cells were harvested 
with cell scraper and transferred to a 1.5 ml Eppendorf tube on ice. Cells were homogenized 
by gently triturating with a 200 µl pipette and incubated for 10 min at 37°C. Then 100 µl of 
each sample were centrifuged at 350x g at RT for 5 min to pellet unbroken cells or tissue 
debris. The supernatant was transferred to ultracentrifuge tubes and centrifuged at 100,000 
x g (~32785.901 rpm, Rotor type 45 Ti) at 37°C for 1h to pellet F-actin and keep the G-actin in 
the supernatant. Subsequently, the supernatant was gently transferred into fresh tubes, 100 
µl of F-actin depolymerization buffer (G-actin/F-actin in vivo assay kit) was added to each 
pellet and incubated for 1h on ice and samples were mixed every 15 min to allow complete 
F-actin depolymerization to G-actin. To denature proteins, 25 µl SDS buffer (G-actin/F-actin 
in vivo assay kit) were added to each pellet as well as to each supernatant sample and mixed 
well. G-actin quantification was performed by SDS-page. 
 
b) SDS-polyacrylamide gel electrophoresis (SDS-page)  
The principle of SDS-page is based on the separation of proteins under the influence 
of electric field within the gel matrix. SDS-page was performed on a 5% stacking phase gel 




and a 12% resolving phase gel. The rack with polymerized gels was placed into 
electrophoresis chamber, filled with ice-cold electrophoresis buffer and 10 µl of each sample 
were loaded in the gel columns. To assess G-actin protein amounts in the loaded samples, G-
actin protein standards (G-actin/F-actin in vivo assay kit) were additionally run through the 
gel in amounts of 10, 20, 50 ng G-actin in 15 µl depolimerization/SDS buffer. To define the 
molecular weight of loaded proteins, a molecular weight marker (dual protein standard) was 
loaded and separated in parallel. G-actin was expected at 43 kDa. The electrophoresis was 
run with an electrophoresis power supply first with a voltage of 50 V to allow samples to 
enter the stacking phase gel without smearing for around 15 min. Then the voltage was 
raised to 100V and let stable until the smallest proteins were reaching the bottom of the gel. 
c) Immunoblotting and band visualisation 
To transfer the proteins to a nitrocellulose membrane a Mini Trans-Blot Cell setup 
was used. Loading the blotting cassette was performed by packing the gel next to the 
membrane between two sheets of Whatman filter paper and fiber pads which were 
previously soaked in transfer buffer. The cassette was placed in the transfer buffer-filled 
Mini Trans-Blot Cell in the direction that proteins could be transferred from cathode (from 
gel) to anode (to membrane). The blotting was performed with 25V ON at 4 °C. After protein 
transfer, the membrane was blocked with 5% non-fat milk in TBS-T for 30-60 min at RT. The 
membrane was rinsed 3 times for 10 min and incubation with the G-actin antibody (rabbit, 
polyclonal, 1:500, G-actin/F-actin in vivo assay kit) was performed in 1% non-fat milk in TBS-
T for 1h at RT, followed by rinsing the membrane 3 times for 10 min with TBS-T. The 
treatment with secondary anti-rabbit antibody coupled to horseradish peroxidase (HRP) 
(1:1000) in 1% non-fat milk in TBS-T was performed for 0.5-1h at RT. Membrane was then 
rinsed 5 times for 10 min with TBS-T and finally treated with chemiluminescent reagents to 
detect the bands of G-actin at 43 kDa. For the chemiluminescent reaction the solution of 
ECL-1 was mixed in equal parts with ECL-2 and added to the membrane for a minimum of 1 
min allowing the antibody coupled-HRP to react with luminol. Afterwards membranes were 
exposed to autoradiography films (HyperfilmTMECLTM) in different time intervals of 10-60 s 
with the help of an autoradiography cassette. The films were developed with a Curix 60 
Developer. 
 




2.2.3.9. Evaluation of G-/F-actin ratio in hippocampal cultures 
To evaluate the ratio of G-actin from the supernatant and F-actin from the pellet 
G-actin bands from autoradiography, films were scanned and band intensities were analyzed 
with the ImageJ gel analysis method. Finally, the G-actin amount of supernatant divided by 
G-actin amount of the pellet revealed the ratio between G-/F-actin in the sample and was 
compared between the groups. 
 
2.2.4. Statistics 
Statistical analyses were conducted using Kyplot software. We assumed the data 
obtained being normally distributed, therefore applying parametric statistical methods, 
which are considered valid for most biological samples. Data from human tissue analysis was 
compared between all 3 groups (yc vs. amc, amc vs. PD or yc vs. PD) using one-way ANOVA 
with Tukey Kramer post-hoc test. For the in vivo mouse experiments, group comparisons 
were always referred to the adequate control (e.g. LAA/PBS vs. 6-OHDA/PBS; 
6-OHDA/control-shRNA vs. OHDA/ROCK2-shRNA), thus one-way ANOVA followed by 
Dunnett´s test were used. In vitro experiments were statistically evaluated by one-way 
ANOVA followed by Dunnett´s test. The applied statistical test and number of experiments is 
indicated in each figure legend. Data are presented as mean ± standard error of the mean 












3.1. Analysing the human brain: Is there a regeneration failure in PD? 
To answer the question how and to what extent intrinsic regenerative capacities in 
the nigrostriatal system of Parkinson’s disease (PD) cases may be inhibited, we performed an 
immunohistochemical analysis of human brain tissue to elucidate if the expression levels of 
certain growth regulating proteins are altered. To estimate the individual disease 
progression from available patient cases, well-known features specifying anatomical 
characteristics of PD were evaluated by immunohistochemistry as well.  
 
3.1.1. Immunohistochemical characterization of patient cases 
The different structural constitution of human midbrain and striatal brain sections of 
three example patient cases –one from each group- is visualized by tyrosine hydroxylase 
(TH-) immunostaining in Figure 3.1/1-A. The upper panel illustrates the putamen (PU) and 
the caudate nucleus (NC), divided by the internal capsule (CI) in exemplary cases of a young 
control (yc), an age-matched control (amc) and a PD patient. The NC is adjacent to the lateral 
ventricle and the PU is separated by the external capsule from the insular cortex. These 
adjacent structures were not present in all sections and therefore not further investigated. 
The decrease in TH-immunoreactivity (TH-IR) in the striatum was obviously detectable in PD 
cases compared to yc (Figure 3.1/1-A, upper panel, right micrograph), although there was no 
significant decrease in TH-IR fiber amount by evaluation of the mean TH-IR in the PU from all 
groups. Nevertheless a strong trend towards less TH fiber density was ascertainable in PD 
cases (46.05 ± 2.33 TH-IR signal) compared to both control groups (yc = 68.19 ± 8.15 TH-IR 
signal, amc = 58.06 ± 7.77 TH-IR signal) (Figure 3.1/1-B). 
The lower panel in Figure 3.1.1-A shows brain sections through the midbrain of yc, 
amc and PD cases. The substantia nigra (SN) and the ventral tegmental area (VTA) appeared 
from the TH-staining in a brown stripe of dopaminergic neurons between the red nucleus 
(NR) and the pedunculus cerebri (PC). In PD cases the TH-IR in the SN was strongly 
decreased, which was already detectable from overview micrographs (Figure 3.1/1-A, lower 
panel, right micrograph) caused by the loss of TH-IR cells (Figure 3.1/1-A, lower panel, 




detail). The relative number of dopaminergic neurons per individual was estimated by 
stereological counting of the TH-IR cells in one unilateral section through the SN per case. 
The counting of cells with the stereo investigator system allows the automatic selection of 
defined counting frames with same size and inter-frame distance for all cases to calculate 
the number of counted cells in the marked area. The quantified TH-IR cell numbers 
confirmed the significant loss of around 65% dopaminergic neurons in PD patients with a 
mean of 3.7 ± 1.33 cells per counting frame (Figure 3.1/1-C, declaring one outlier) compared 
to age-matched (amc = 11.84 ± 1.06 cells per counting frame) and young controls (yc = 10.11 
± 0.98 cells per counting frame). The other midbrain areas were not further investigated. 
 
 
Figure 3.1/1: Immunohistochemical characterization of human brain sections. Micrographs show 
representative TH-DAB-immunostainings and illustrate the investigated areas of the striatum (A, upper panel) 
and substantia nigra (A, lower panel, inset: magnification from SNpc) in young controls (yc), age-matched 




controls (amc) and PD cases (PD). CI = internal capsule, NC = caudate nucleus, NR = red nucleus, PC = 
pedunculus cerebri, PU = putamen, SN = substantia nigra. Quantification of dopaminergic fiber density in 
putaminal striatum (B, n.s.; yc: n=5; amc: n=6; PD: n=7) and cell number in SNpc (C, yc: n=4; amc: n=6; PD: n=7). 
Data is given in averaged values for each case, bars represent means per group ± SEM. *P<0.05; ***P<0.001 
(One-way ANOVA with Tukey Kramer test for independent comparison between groups). 
 
In addition to the extent of dopaminergic degeneration, the degree of astrocytosis and 
microgliosis in the substantia nigra pars compacta (SNpc) and striatum was evaluated. 
Therefore astrocytes were identified by fluorescence immunohistochemistry against GFAP. 
Concomitant with the dopaminergic degeneration in the nigrostriatal system, there is an 
increase of GFAP-immunoreactivity (GFAP-IR) in the putaminal striatum. This augmentation 
in astrocytic markers was strongly detectable in PD cases and also in the age-matched 
control group, while in contrast, the yc showed less GFAP-IR signal (Figure 3.1/2-A, upper 
panel). The quantification of GFAP-IR cells confirmed these findings resulting in statistically 
significant differences in GFAP-IR structures between the groups (yc = 8.286 ± 3.079 
GFAP-IR; amc = 53.030 ± 14.415 GFAP-IR; PD = 116.404 ± 20.632 GFAP-IR), although 
interindividual differences within one group were pronounced (Figure 3.1/2-B). The analysis 
of GFAP-IR in the SNpc (Figure 3.1/2-A, lower panel) did not show significant differences in 
PD patients (PD = 170.430 ± 33.598 GFAP-IR) compared to young (yc = 87.215 ± 32.350 
GFAP-IR) or age-matched controls (amc = 143.005 ± 38.409) (Figure 3.1/2-C). However, there 
seemed to be a trend to enhanced astrogliosis in PD patients and age-matched controls. 





Figure 3.1/2: Immunohistochemical examination of astrocytes in the SNpc and striatum in human brain 
sections with the astrocytic marker GFAP. Representative micrographs from the putaminal striatum showed an 
increased GFAP-IR signal in PD cases compared to controls (A, upper panel, quantified in B: yc: n=4; amc: n=6; 
PD: n=7), while in the SNpc no difference in GFAP-IR was detectable (A, lower panel, quantified in C: yc: n=4; 
amc: n=6; PD: n=6). Data is given in averaged values from each case, bars represent means per group ± SEM. 
*P<0.05; **P<0.01 (One-way ANOVA with Tukey Kramer test for independent comparison between groups). 
 
To assess the inflammatory response to dopaminergic degeneration in the nigrostriatal 
system in PD an immunohistochemical analysis of microglia infiltration was performed. 
Immunolabeling of Iba1 denotes all microglia, thus the amount of Iba1-IR cells in the 
striatum was examined (Figure 3.1/3-A). The quantification of the Iba1 immunoreactivity 
(Iba1-IR) in the striatum resulted in no significant differences after group comparison (Figure 
3.1/3-C), possibly due to high interindividual variance in the young control group (yc = 7.31 
± 2.77 Iba1-IR), which was not as pronounced in age-matched controls (amc = 2.93 ± 0.9 




Iba1-IR). Interestingly, except one case, all PD brains showed less Iba1-IR (PD = 4.85 ± 2.29 
Iba1-IR). The degeneration of dopaminergic neurons entailed the transformation of 
microglia into phagocytotic active microglia, which eliminate cell debris. In this state the 
phagocytic active microglia exhibit an amoeboid shape (Figure 3.1/3-B, arrows) and are 
considered to foster degeneration by producing detrimental molecules (Nakajima & Kohsaka 
2001). In order to identify phagocytic active microglia in human brains of PD cases and 
controls an immunolabeling for the macrophagic marker ED1 was performed (Figure 3.1/3-
B). Interestingly, there were no significant changes in the amount of ED1-IR cells observable, 
neither in the SNpc (yc = 10.25 ± 0.680 ED1-IR, amc = 16.57 ± 2.319 ED1-IR, PD = 14.38 
± 2.114 ED1-IR cells per visual field, data not shown) nor in the striatum (yc = 7.32 ± 0.591, 
amc = 9.6 ± 1.018, PD = 10.9 ± 1.220 ED1-IR cells per visual field), however there were 
pronounced interindividual differences in the PD group (Figure 3.1/3-D). 
 





Figure 3.1/3: Immunohistochemical assessment of infiltrated microglia into the striatum on human brain 
sections. Staining the entire microglia in the putamen with Iba1 is represented by micrographs of each group in 
A and the statistical quantification of Iba1-IR cells is displayed in B (yc: n=5; amc: n=5; PD: n=7) resulting in no 
differences in microglia numbers. Exemplary images of ED1-IR phagocytic microglia (white arrows) in the 
striatum are shown in C. Quantitative evaluation showed no differences in ED1-IR between the groups (D, yc: 
n=5; amc: n=5; PD: n=6). Data is given in averaged values from each case; bars represent means per group 
± SEM. 
 
3.1.2. Analysis of growth-associated proteins and presynaptic configuration 
To investigate the intrinsic regeneration capacity of the nigrostriatal system the main 
focus of the study included the investigation of the axonal growth-associated protein-43 
(GAP-43). To evaluate the expression levels of this protein, especially in dopaminergic 
neurons, co-staining of GAP-43 together was TH were performed. Interestingly, striatal TH 




fibers were rarely detectable, only very thick ones were labelled sporadically by the 
antibody. Thus co-localization of TH and GAP-43 was not possible in the striatum of human 
brain sections. Consequently GAP-43 expression was evaluated from the immunofluorescent 
signal in all tissue structures of the putamen. Surprisingly, the GAP-43-IR did not indicate any 
apparent differences in expression between the groups (Figure 3.1/4-A), thus the 
quantification resulted in no detectable changes in mean GAP-43 protein expression in PD 
cases (PD = 47.141 ± 3.023 GAP43-IR) compared to age-matched (amc = 26.302 ± 4.833 
GAP-43-IR) and young controls (yc = 27.141 ± 2.756 GAP-43-IR) (Figure 3.1/4-B). 
To assess the density of striatal pre-synaptic connections, the synaptic vesicle protein 
synaptophysin (synphy) was detected by immunohistochemical labeling. Similar to the 
GAP-43 expression, the density of the synphy fluorescence signal seemed to be not altered 
in amc or PD cases (Figure 3.1/4-C), however the quantification of the mean 
synphy-immunoreactivity (synphy-IR) showed a slight trend to decreased synaptophysin 
density in PD cases. The quantification showed no significant changes of the synaptic protein 
(yc = 10.849 ± 1.526 synphy-IR, amc = 11.738 ± 1.011 synphy-IR, PD = 8.469 ± 2.402 synphy-
IR, Figure 3.1/4-D), probably due to strong interindividual differences in the PD group.  
 
 
Figure 3.1/4: Analysis of striatal GAP-43 expression and synaptic integrity. Representative micrographs of 
GAP-43-immunofluorescence (IF) signal in the putamen of young controls (yc), age-matched controls (amc) and 
PD cases (PD) (A). Evaluation of GAP-43 protein expression in the striatum resulted in similar mean 
fluorescence signal in the groups (B, yc: n=5; amc: n=6; PD: n=7). The putaminal synaptophysin 
immunofluorescence (synphy-IF) is exemplary illustrated in C, and the statistical group comparisons did not 




show obvious differences (D, yc: n=5; amc: n=6; PD: n=7). Data is given in averaged values from each case; bars 
represent means per group ± SEM (One-way ANOVA). 
 
In the SN the dopaminergic neurons were clearly identified by immunofluorescent 
staining against TH. To examine the GAP-43 protein amount in dopaminergic somata and 
processes, co-stainings for TH and GAP-43 were performed (Figure 3.1/5-A). One difficulty in 
measuring the GAP-43 amount in TH-IR cells was the strong presence of neuromelanin, thus 
the GAP-43 amount had to be quantified in areas of the cell where neither the nucleus nor 
neuromelanin was localized. This evaluation revealed sparse GAP-43-IR in dopaminergic cells 
and there were no differences in mean expression levels detectable between the groups (yc 
= 38.780 ± 2.064, amc = 34.150 ± 3.317, PD = 29.584 ± 2.111, Figure 3.1/5-B). There was a 
distinct trend for decreased GAP-43 protein expression in TH-IR cells in PD cases, which 
however was not statistically relevant. In contrast, the adjacent SNpc neuropil showed 
strong GAP-43-IR in all cases and a significantly higher mean GAP-43 protein expression in 
young controls (yc = 65.571 ± 4.801 GAP-43-IR), while in age-matched controls and PD cases 
the GAP-43 signal was less intense (amc = 43.965 ± 2.953, PD = 42.29 ± 4.271 GAP43-IR, 
Figure 3.1/5-C). To allocate the GAP-43 expression to certain structures in the nigral 
neuropil, it was correlated to synaptophysin expression. Co-stainings of both proteins 
showed no significant co-localization, thus the GAP-43 expression primarily seems to be 
outside of the presynapse (Figure 3.1/5-A, last panel). In addition to the finding of decreased 
nigral GAP-43 protein expression in PD, the averaged synphy-IR was also intensely reduced 
in the SNpc (Figure 3.1/5-D) of PD cases (PD = 5.282 ± 1.450 synphy-IR), however 
interindividual synaptophysin expression was highly variable. In age-matched controls this 
decrease in synaptic configuration seems not as pronounced as in PD cases (amc 
= 7.048 ± 1.140 synphy-IR), nevertheless there is an apparent trend to diminished synphy-IR 
compared to young controls (yc = 10.905 ± 0.895 synphy-IR).  
 





Figure 3.1/5:  GAP-43 expression in dopaminergic neurons and neuropil of SN. Representative micrographs of 
multiple immunostainings of TH, GAP-43 and synaptophysin in the SNpc are illustrated in A. Results from the 
statistical evaluation of GAP-43-IR in the TH-IR cell somata (B) and in the nigral neuropil (C) depicted a decline 
in GAP-43 protein expression in the amc and PD groups compared to yc (B/C: yc: n=4; amc: n=6; PD: n=6). 
Synaptic composition is demonstrated by representative micrographs of synaptophysin protein expression in 
the SNpc (A) and the corresponding statistical analysis of synphy-IR is visualized in graph D (yc: n=4; amc: n=6; 
PD: n=7). Data is given in averaged values from each case; bars represent means per group ± SEM. *P<0.05; 
**P<0.01 (One-way ANOVA with Tukey Kramer test for independent comparison between groups). 
 
3.1.3. Investigation of the growth-inhibitory protein Rho kinase (ROCK2) in 
human brain sections 
Complementary to the pro-regenerative protein GAP-43, we were additionally 
interested in the role of the growth-inhibitory protein ROCK2 in PD. One characteristic 
feature of active ROCK is to induce, via phosphorylation of downstream proteins, stress fiber 




formation and growth cone collapse, leading to inhibition of regenerative fiber elongation. 
Immunohistochemical signals in the SNpc from PD cases and controls disclosed a very weak 
expression of this protein. Interestingly, ROCK2 showed a distinct puncta-like staining with 
ubiquitous distribution, less pronounced in TH-IR somata as in the neuropil (Figure 3.1/6-A). 
The evaluation of possible alterations in ROCK2 expression did not indicate any significant 
differences in expression between the groups, neither in the somata of dopaminergic 
neurons nor in the neuropil of the SNpc (Figure 3.1/6-B and 3.1/6-C), however with 
pronounced interindividual differences in protein expression in all groups.  
 
 
Figure 3.1/6: Analysis of ROCK2 expression in the substantia nigra of PD cases and controls. Representative 
micrographs of ROCK2-IR are illustrated in A, upper panel and double immunoreactive ROCK2/TH co-stainings 
in A, lower panel. ROCK2-IR was evaluated in TH-IR cells and quantified in B. ROCK-IR in the adjacent neuropil 
was measured in TH-negative areas and the quantification is illustrated in C. The statistical comparison resulted 
in no differences in expression levels between the groups (B/C, yc: n=4; amc: n=6; PD: n=7). Data is given in 
averaged values from each case; bars represent means per group ± SEM (One-way ANOVA). 
 
In the striatum, the ROCK2 protein expression showed similar distribution patterns of 
the punctate structures as in the SNpc. The overall ROCK2-IR signal was quite low in all 
sections (Figure 3.1/7-A). Measuring the amount of averaged ROCK2-immunofluorescence 
(ROCK2-IF) in the entire striatal tissue structures, by randomly chosen areas from the 
acquired images, resulted in no clear expression changes in the groups (Figure 3.1/7-B). 
Interestingly, in PD cases and age-matched controls, a number of single cells with an 




intensive ROCK2-immunoreactivity (Figure 3.1/7-A, arrows) could be noticed, which were 
quantified in number. We discovered a distinct increase in these ROCK2-IR cells in PD cases 
(PD = 34.013 ± 5.288 ROCK-IR cells/visual field) as compared to young controls (yc = 
17.177 ± 3.0 ROCK-IR cells/visual field). A similar increase was observed in age-matched 
controls as well (amc = 32.342 ± 3.471 ROCK-IR cells/visual field, Figure 3.1/7-C), but this was 
not significantly different to young controls.  





Figure 3.1/7: Quantification of ROCK2-IR in the striatum of PD cases and controls. Representative micrographs 
illustrate the ROCK2 protein expression in the putamen of young and age-matched controls and PD cases (A). 
The evaluation of the general ROCK2 fluorescence signal resulted in no detectable differences between the 
groups (B, yc: n=4; amc: n=6; PD: n=7). White arrows point to single cells with high ROCK-IR (A). Quantification 




of these ROCK-IR cells resulted in significantly increased numbers in PD cases (C, yc: n=5; amc: n=6; PD: n=7). 
These cells could be identified by double-immunostaining of ROCK2 and GFAP as astrocytes (D) and with co-
staining of ROCK2 and Iba1 partially as microglia (E). Quantification of these double-immunoreactive cells 
resulted in significantly increased numbers of ROCK-IR astroglia (F, yc: n=5; amc: n=6; PD: n=7) and in slightly 
enhanced counts of ROCK2-IR microglia (G, yc: n=5; amc: n=5; PD: n=7). Data is given in averaged values from 
each case, bars represent means per group ± SEM. *P<0.05 (One-way ANOVA with Tukey Kramer test for 
independent comparison between groups). 
 
In order to clarify the role of these ROCK2-IR cells during ageing or in the development of PD, 
we tried to identify these cells. Because of their morphology these cells appeared potentially 
as glial cells, featuring processes and smaller nuclei than neurons. With immunostainings 
against GFAP and Iba1 in combination with ROCK2 (Figure 3.1/7-D and E) the amount of 
ROCK2-IR astrocytes and microglia was quantified. The analysis revealed that the average 
number of ROCK-IR astrocytes was significantly higher in PD cases (PD = 1.924 ± 0.425 
ROCK2/GFAP-IR cells/visual field) compared to young (yc = 0.573 ± 0.186 ROCK2/GFAP-IR 
cells/visual field) and age-matched controls (amc = 1.067 ± 0.327 ROCK2/GFAP-IR cells/visual 
field). However, also age-matched controls tended to show increased numbers of ROCK2-IR 
astrocytes (Figure 3.1/7-F), including pronounced interindividual differences. Regarding the 
double staining of Iba1 and ROCK2 the analysis revealed no striking co-labeling of microglia 
in any groups (Figure 3.1/7-E). In the PD group there were three cases with remarkable 
amount of ROCK-IR microglia, however the mean number of ROCK-IR and Iba1-IR cells was 
not significantly increased in PD cases (PD = 0.76 ± 0.2 ROCK2/Iba1-IR cells/visual field) 
compared to the controls (yc = 0.43 ± 0.16 ROCK2/Iba1-IR cells/visual field and amc = 
0.37 ± 0.08 ROCK2/Iba1-IR cells/visual field) (Figure 3.1.7-G). Taken together, there was 
evidence for an elevated number of striatal astrocytes that express ROCK2 in conspicuous 
amounts, which was accompanied with a trend to more ROCK2-IR microglia in PD cases. 
These findings would explain the higher number of striatal ROCK-IR cells in brains from PD 
cases, suggesting an important role forROCK2 in striatal glial cells in the progression of PD. 
 
 




3.2. The role of ROCK2 inhibition in the 6-OHDA mouse model of PD 
Since it is known that pharmacological ROCK2 inhibition can directly or indirectly 
affect the neuronal survival and regeneration, we examined in the present investigation the 
neuron-specific impact of virus-mediated ROCK2 downregulation in the 6-OHDA mouse 
model of PD. To determine the neuroprotective potential of AAV.shRNA-mediated inhibition 
of ROCK2, mice received a unilateral right-sided striatal 6-OHDA lesion targeting the axonal 
terminals of the nigrostriatal tract. Simultaneously they were injected with a neuron specific 
AAV.ROCK2-shRNA into the ipsilateral SN with two different virus titers.  
 
3.2.1. AAV mediated gene transfer leads to effective dsRed expression in neurons 
of the substantia nigra 
In order to confirm the successful transduction of the shRNA construct into neurons 
of the SNpc and to validate the neuronal specificity of the AAV2, a co-localization of the 
vector-expressed fluorophore dsRed and different marker proteins for neurons and glial cells 
was performed. The cell type driven fluorophore expression was exclusively co-localized with 
the immunohistochemical staining against the neuronal nuclei marker NeuN for the viral 
vector carrying the ROCK2-shRNA as well as the respective control shRNA (Figure 3.2/1-A). 
Immunostainings for the astrocytic marker GFAP and the microglia epitope Iba1 resulted in 
no detectable co-localization with the vector-driven dsRed fluorophore (Figure 3.2/1-B and 
C). Thus, co-localization of the NeuN-immunoreactivity (NeuN-IR) fluorescence signal and 
dsRed revealed strong evidence for an effective transduction of neurons by ROCK2-shRNA. 
 









Figure 3.2/1: Immunohistological demonstration of AAV transduction into neurons of the substantia nigra in 
vivo. The co-localisation of the intracellularly expressed fluorophore dsRed and the neuronal marker NeuN 
showed evidence for targeting nigral neurons with either the control- or the ROCK2-shRNA (A, arrows depict 
co-localisation of NeuN and dsRed). The cell type specificity of the synapsin-promoter-driven dsRed expression 
is underscored by additional immunolabelings for Iba1 (B) and GFAP (C). 
 
3.2.2. shRNA-mediated ROCK2 downregulation increases dopaminergic neuron 
survival after 6-OHDA intoxication 
At four weeks after the lesion the immunohistochemistry of TH-IR structures 
demonstrated a drastic loss of TH-IR cells in the ipsilateral SNpc (Figure 3.2/2) caused by the 
unilateral 6-OHDA intoxication. The quantification of TH-IR cells of the ipsilateral SN via 
stereological counting displayed a significant decrease of about 60% of TH-IR neurons in 
6-OHDA lesioned animals in comparison to vehicle controls (LAA/PBS = 11083.2 ± 503.4 cells 
vs. 6-OHDA/PBS = 4019.2 ± 640.2 cells, Figure 3.2/2-A-B). Simultaneous treatment with 
ROCK2-shRNA in animals lesioned with 6-OHDA resulted in an attenuated loss of TH-positive 
neurons (Figure 3.2/2D-F). In detail, animals transduced with AAV.ROCK2-shRNA in a titer of 
0.25x 108 TU had significantly more TH-positive neurons as compared to control-shRNA 
(6-OHDA/ROCK2-shRNA0.25 = 6529.2 ± 696.9 cells vs. 6-OHDA/control-shRNA = 
2982.1 ± 704.3 cells; Figure 3.2/2-F). Introduction of the higher titer (1.0x 108 TU) of 
AAV.ROCK2-shRNA also resulted in an increased cell survival after 6-OHDA intoxication, 
however not reaching statistical significance as compared to control virus (6-OHDA/ROCK2-
shRNA1.0 = 4982.9 ± 645.1 cells; Figure 3.2/2-F). 






Figure 3.2/2: Immunohistological analysis of tyrosine hydroxylase (TH) and Nissl cells in the substantia nigra 
(SN) four weeks after 6-OHDA lesion of the striatum and introduction of a ROCK2-shRNA via viral vector into 
the SN. (A-E) Representative micrographs of SN immunolabeled against TH and treated with vehicle (LAA/PBS, 
A, n=4), 6-OHDA/PBS (B, n=7), 6-OHDA/control-shRNA in a titer of 1.0x 10
8 
TU/µl (ctrl-shRNA, C, n=5), 
6-OHDA/ROCK2-shRNA in a titer of 0.25x 10
8  
TU/µl (ROCK2-shRNA0.25, D, n=4) or 6-OHDA/ROCK2-shRNA in a 
titer of 1.0x 10
8 
TU/µl (ROCK2-shRNA1.0, E, n=5). Quantitative stereological analysis of TH (F) and Nissl positive 
cells (G) in the SNpc depicted a massive loss of TH-IR cells after 6-OHDA intoxication. Data are given as 
means ± SEM. **P<0.01 (one-way ANOVA with Dunnett´s test compared to control-shRNA). 
 
Nissl staining was performed to identify the entirety of all neurons in the SN. From 
the Nissl positive cell number it can be concluded whether the loss of TH-IR resulted from 




death of dopaminergic neurons or if there is a 6-OHDA-induced downregulation of TH 
expression and therefore cells would appear as Nissl positive anyway. As demonstrated in 
Figure 3.2/2-G, nigral 6-OHDA injection leads to a severe loss of Nissl positive cells in the 
ipsilateral SN, indicating robust dopaminergic degeneration in all of the lesioned groups 
(LAA/PBS = 15377.5 ± 775.4 cells vs. 6-OHDA/PBS = 6301.8 ± 753.9 cells; 6-OHDA/ROCK2-
shRNA0.25 = 11597.6 ±915.5 cells and 6-OHDA/ROCK2-shRNA1.0 = 9312.7 ± 1189.4 cells vs. 
6-OHDA/control-shRNA = 7407.2 ± 1169.1 cells; Figure 3.2/2-G). ROCK2-shRNA-treated 
groups showed the same trend of attenuated cell loss as depicted in TH-cell counting, 
confirming the neuroprotective effects on dopaminergic neurons. 
 
3.2.3. ROCK2 downregulation has only mild effects on dopaminergic fiber density 
and dopamine levels in the striatum 
To determine the protective effect of AAV.shRNA-mediated downregulation of 
ROCK2 on the nigrostriatal terminals after 6-OHDA lesion, the density of TH-positive fibers in 
the striatum was investigated. The relative striatal dopaminergic fiber density was examined 
by measuring the mean TH-immunoreactivity (TH-IR) from the lesioned as well as from the 
unlesioned hemisphere (TH-IR lesioned/TH-IR unlesioned). In the micrographs in Figure 
3.2/3-B-E there is a severe decrease of TH-IR detectable in the dorsal striatum of intoxicated 
animals at four weeks after cerebral 6-OHDA injections. The quantification of TH-IR showed 
a significant reduction of approximately 55% in the 6-OHDA control group as compared to 
vehicle injected animals (LAA/PBS = 98.5 ± 1.2% TH-IR vs. 6-OHDA/PBS = 44.1 ± 5.3% TH-IR; 
Figure 3.2/3). Animals simultaneously treated with AAV.ROCK2-shRNA in both titers 
displayed less fiber decline than the lesion group compared to the vehicle injected mice. 
However, there was only a strong trend towards attenuated TH-fiber loss in ROCK2 shRNA-
treated animals by comparing them to the adequate control-shRNA group, not reaching 
significance due to the big variances in the groups (6-OHDA/ROCK2-shRNA0.25m = 72.2 ± 
6.2% TH-fiber density and 6-OHDA/ROCK2-shRNA1.0 = 69.0 ± 9.9% TH-fiber density vs. 
6-OHDA/control-shRNA = 49.9 ± 2.1% TH-fiber density; Figure 3.2/3-F). 





Figure 3.2/3: Immunohistological analysis of striatal TH density four weeks after 6-OHDA lesion of the striatum 
and introduction of a ROCK2-shRNA via viral vector into the SN. (A-E) Representative micrographs of injected  
striata immunolabeled against TH with the following groups: vehicle (LAA/PBS A, n=5), 6-OHDA/PBS (B, n=7), 
6-OHDA/control-shRNA (ctrl-shRNA, C, n=5), 6-OHDA/ROCK2-shRNA in a titer of 0.25x 10
8 
TU/µl (ROCK2-
shRNA0.25, D, n=5) or 6-OHDA/ROCK2-shRNA in a titer of 1.0x 10
8 
TU/µl (ROCK2-shRNA1.0, E, n=4). 
Quantitative analysis of relative striatal TH fiber density (lesioned side/unlesioned side in %) is depicted in F. 
Data is shown as means ± SEM. *P<0.05; **P<0.01; ***P<0.001 (One-way ANOVA with Dunnett´s test for 
comparison with vehicle group). 
 




In order to correlate the histological results of the striatal TH-fiber density to a 
functional preservation of these axonal terminals a high performance liquid chromatography 
(HPLC) was performed four weeks after AAV.ROCK2-shRNA treatment. For this 
neurochemical analysis of dopamine and its metabolites fresh brain tissue was processed to 
purify the molecules for HPLC. Results from chromatographic detection depicted that the 
acute 6-OHDA intoxication had almost completely depleted the striatal levels of dopamine 
after 4 weeks (DA: LAA/PBS = 12.18 ± 0.57 ng/mg vs. 6-OHDA/PBS = 0.40 ± 0.17 ng/mg; 
Figure 3.2/4-A). This depletion of dopamine was consistent in all treatment groups and no 
effect of ROCK2-shRNA transduction could be observed (6-OHDA/ROCK2-shRNA0.25 = 
0.51 ± 0.18 ng/mg and 6-OHDA/ROCK2-shRNA1.0 = 2.07 ± 1.01 ng/mg vs. 6-OHDA/control-
shRNA = 1.44 ± 0.56 ng/mg). 
Regarding to the dopamine metabolites HVA and DOPAC a similar depletion of these 
molecules was observed after 4 weeks, again with no detectable impact on metabolic levels 
between ROCK2-shRNA treated groups and controls (Figure 3.2/4-B: HVA: LAA/PBS = 1.98 
± 0.12 ng/mg vs. 6-OHDA/PBS = 0.71 ± 0.11 ng/mg; 6-OHDA/ROCK2-shRNA0.25 = 0.8 ± 0.06 
ng/mg and 6-OHDA/ROCK2-shRNA1.0 = 0.83 ± 0.18 ng/mg vs. 6-OHDA/control-shRNA = 
0.97 ± 0.12 ng/mg and Figure 3.2/4-C: DOPAC: LAA/PBS = 2.74 ± 0.16 ng/mg vs. 6-OHDA/PBS 
= 0.26 ± 0.1 ng/mg; 6-OHDA/ROCK2-shRNA0.25 = 0.3 ± 0.12 ng/mg and 6-OHDA/ROCK2-




Figure 3.2/4: HPLC analysis of dopamine and dopamine metabolites in the striatum at four weeks after striatal 
6-OHDA lesion and nigral transduction with AAV.ROCK2-shRNA. Quantification of dopamine (DA) (A), 
homovanillic acid (HVA) (B) and 3,4-dihydroxyphenylacetic acid (DOPAC) (C) resulted in no observable 




differences between the groups, included vehicle (LAA/PBS, n=10), 6-OHDA/PBS (n=8), 6-OHDA/control-shRNA 
(ctrl-shRNA, n=10); 6-OHDA/ROCK2-shRNA in a titer of 0.25x 10
8 
TU/µl (ROCK2-shRNA0.25, n=10) and 
6-OHDA/ROCK2-shRNA in a titer of 1.0x 10
8 
TU/µl (ROCK2-shRNA1.0, n=11). Data are given as means ± SEM. 
***P<0.001 (One-way ANOVA with Dunnett´s test compared to vehicle group). 
 
3.2.4. ROCK2 downregulation via AAV-shRNA has only minor effects on behavioral 
outcome 
In addition to the histological and neurochemical analysis, mice were tested for their 
motor behavior in different motor exercises at two and four weeks after the intracranial 
injections.  
To assess the functional impact of the 6-OHDA lesion on the nigrostriatal system, we 
performed the apomorphine turning test. The subcutaneously applied dopamine agonist 
apomorphine induces a hyperactivation of postsynaptic striatal dopamine receptors forcing 
lesioned mice to contralateral (ctl) rotational movements (turns). The number of turns a 
mouse completed was counted and could be used as an indicator for individual 6-OHDA 
lesion size. As expected, all intoxicated mice showed a strong contralateral rotation behavior 
after two weeks, while vehicle injected mice exhibited a naturally explorative behavior to 
both sides (LAA/PBS = 6.2 ± 0.63 ctl turns/20 min and 6.9 ± 2.17 ipl turns/20 min; 
6-OHDA/PBS = 152.5 ± 15.94 ctl turns/20 min and 1.9 ± 0.87 ipl turns/20 min; 
6-OHDA/ROCK2-shRNA0.25 = 134.83 ± 17.62 ctl turns/20 min and 0.75 ± 0.39 ipl turns/20 
min; 6-OHDA/ROCK2-shRNA1.0 = 155.09 ± 24.20 ctl turns/20 min and 2.27 ± 0.70 ipl 
turns/20 min; 6-OHDA/control-shRNA = 100.2 ± 14.57 ctl turns/20 min and 1.4 ± 0.7 ipl 
turns/20 min; Figure 3.2.5-A, upper diagram). The comparison between the ROCK2-shRNA 
and the control-shRNA treated group resulted in no turning alteration.  
In all groups injected with 6-OHDA a small increase in rotation behavior could be 
observed in the test after four weeks, however there was again no diminished turning 
number of AAV.ROCK2-shRNA injected mice detectable (LAA/PBS = 3.0 ± 0.46 ctl turns/20 
min and 3.7 ± 0.93 ipl turns/20 min; 6-OHDA/PBS = 169.88 ± 14.64 ctl turns/20 min and 
0.25 ± 0.23 ipl turns/20 min; 6-OHDA/ROCK2-shRNA0.25 = 162.92 ± 22.26 ctl turns/20 min 
and 0.08 ± 0.08 ipl turns/20 min; 6-OHDA/ROCK2-shRNA1.0 = 165.82 ± 26.12ctl turns/20 min 
and 0.27 ± 0.19 ipl turns/20 min; 6-OHDA/control-shRNA = 126.2 ± 21.40 ctl turns/20 min 
and 0.5 ± 0.47 ipl turns/20 min; Figure 3.2/5-A, lower diagram).  




Another test to estimate unilateral lesion extent is the cylinder rearing test. The 
mouse natural exploration behavior was utilized to examine lateralized motor coordination 
at two and four weeks after 6-OHDA injection. In general, the unilateral lesion led to a lower 
frequency of contralateral forelimb usage to touch the cylinder walls during rearing. As 
expected, a significant increase of rears with using the right paw in comparison to the left 
paw was detected in unilaterally 6-OHDA-lesioned animals, due to the right striatal lesions 
and lower innervations of the left paw at two weeks after intoxication (Figure 3.2/5-B, upper 
diagram; 6-OHDA/PBS = right: 27.83 ± 6.51% vs. left: 1.56 ± 0.82%). Unlesioned animals were 
touching the walls with either the right or the left paw in equal amounts (LAA/PBS = right: 
1.66 ± 0.71%, left: 1.68 ± 0.69%), but in general they used the single paws less often than the 
lesioned mice. The frequency of using the right paw more often than the left paw was not as 
pronounced in AAV.ROCK2-shRNA injected animals compared to lesion controls, however 
there was no difference to the control-shRNA group observable (6-OHDA/ROCK2-shRNA1.0 = 
right: 16.03 ± 3.9%; 6-OHDA/ROCK2-shRNA0.25 = right: 14.94 ± 4.23% vs. 6-OHDA/control-
shRNA = right:9.52 ± 4.87%).  
After four weeks, the cylinder test observations resulted in the same outcome, the 
6-OHDA lesioned animals were using more often their right paws for touching the wall, than 
the left one and compared to unlesioned animals there was still a significant difference in 
paw using frequency (Figure 3.2/5-B, lower diagram; 6-OHDA/PBS = right: 15.42 ± 2.85% vs. 
left: 2.82 ± 1.81% vs. LAA/PBS = right: 4.82 ± 1.75%, left: 4.89 ± 1.91%). Treatment with 
AAV.ROCK2-shRNA seemed to have no beneficial effect on paw usage after four weeks. 
To evaluate influences of AAV.ROCK2-shRNA treatment on motor endurance in 
6-OHDA lesioned mice the rotarod test with accelerated speed of the running wheel over 
time was employed. Two weeks after intracerebral injections the motor performance of 
lesioned mice decreased significantly compared to the vehicle injected animals (Figure 
3.2/5-C; LAA/PBS = 196.1 ± 14.56 s vs. 6-OHDA/PBS = 149.63 ± 11.78 s). The rotarod 
performance of animals with 6-OHDA lesion was, however, not significantly different from 
animals injected with control- or ROCK2-shRNA. Therefore the treatment with ROCK2-shRNA 
seemed to have no improving effect compared to the control-shRNA injected group 
(6-OHDA/ROCK2-shRNA0.25 = 165.89 ± 21.49 s, 6-OHDA/ROCK2-shRNA1.0 = 
188.48 ± 26.37 s vs. 6-OHDA/control-shRNA = 179.63 ± 12.36 s). At four weeks after the 
surgeries no lesion impairment for rotarod performance was observed between any groups. 




In order to detect more subtle changes in motor behavior, we employed the Catwalk 
XT gait analysis system at two and four weeks after 6-OHDA-injection. Recording the paw 
prints from below, there were around 80 parameters compiled, considering each single paw, 
as well as the interlimb coordinations and walking patterns. Out of these parameters just a 
few quantifications showed alterations in paw statistics after unilateral 6-OHDA lesion 
compared to unlesioned animals. For example, mice injected with 6-OHDA showed in 
general bigger foot print areas as compared to the vehicle injected group after four weeks, 
especially the print width of the forelimbs increased significantly (LAA/PBS = right front: 
0.59 ± 0.06 cm, left front: 0.6 ± 0.05cm vs. 6-OHDA/PBS = right front: 0.77 ± 0.03 cm, left 
front: 0.78 ± 0.05 cm, **P=0.008; vs. 6-OHDA/ROCK2-shRNA0.25 = right front: 0.73 ± 0.05 
cm, left front: 0.72 ± 0.03 cm, *P=0.042; vs. 6-OHDA/ROCK2-RNA1.0 = right front: 0.73 ± 0.03 
cm, left front: 0.74 ± 0.03 cm, *P=0.039; 6-OHDA/control-shRNA = right front: 0.74 ± 0.03 
cm, left front: 0.73 ± 0.03 cm, *P=0.027). ROCK2-shRNA treatment revealed no significant 
impact on footprint areas, however. 
Focused on the parameter describing the ratio of the maximal paw print intensity 
after initial paw contact with the glass plate in relation to the duration of the paw stand on 
the plate (i.e. Max Intensity At [%] = (Max Intensity At (s)-initial contact)*100)/stand), we 
observed an increase for the right hind (RH) paw in 6-OHDA lesioned mice, while on the 
contrary this parameter decreased for the left hind (LH) paw at four weeks after unilateral 
intoxication (LAA/PBS = RH: 37.42 ± 2.0%, LH: 37.26 ± 2.5% vs. 6-OHDA/PBS = RH: 
48.7 ± 5.9%, LH: 28.7 ± 2.5%; Figure 3.2/5-D). Interestingly, animals treated with ROCK2-
shRNA showed a reduced Max Intensity At [%] regarding the right hind limbs as compared to 
control-shRNA, reaching significance in the group treated with the high virus titer 
(6-OHDA/ROCK2-shRNA0.25 = RH: 37.8 ± 3.17%; 6-OHDA/ROCK2-RNA1.0 = RH: 
32.61 ± 2.32% vs. 6-OHDA/control-shRNA = RH: 41.96 ± 3.17%; Figure 3.2/5-D) at four weeks 
after lesion. Regarding the left hind limbs, Max Intensity At [%] increased in ROCK2-shRNA 
injected mice, although this effect was not statistically significant compared to control-
shRNA treated animals (6-OHDA/ROCK2-shRNA0.25 = LH: 35.88 ± 3.62%; 6-OHDA/ROCK2-
RNA1.0 = LH: 33.36 ± 1.52% vs. 6-OHDA/control-shRNA = LH: 29.93 ± 1.95%; Figure 3.2/5-D). 
Therefore shRNA-mediated downregulation of nigral ROCK2 expression seems to influence 
this parameter, which is altered by the unilateral 6-OHDA lesion. 
 




              
Figure 3.2/5: Analysis of motor behavior two and four weeks after 6-OHDA lesion and simultaneous 
transduction with AAV.shRNA. (A) Quantification of rotation behavior induced by apomorphine treatment at 
two different time points. Numbers of contra- and ipsilateral turns/20min after apomorphine injection with 
LAA/PBS (n=10), 6-OHDA/PBS, (n=8), 6-OHDA/control-shRNA (ctrl-shRNA, n=10), 6-OHDA/ROCK2-shRNA in a 
titer of 0.25x 10
8 




(B) Motor coordination was tested in the cylinder rearing test at two and four weeks after injections. 
Quantification of the relative number of rears against the wall with “both” paws, only the “right” or “left” paw 
or “free” rears. Groups analyzed were LAA/PBS (n=10), 6-OHDA/PBS (n=10 at two and n=8 at four weeks after 
lesion), 6-OHDA/control-shRNA (ctrl-shRNA, n=10), 6-OHDA/ROCK2-shRNA in a titer of 0.25x 10
8 
TU/µl (ROCK2-
shRNA0.25, n=12) and OHDA/ROCK2-shRNA in a titer of 1.0x 10
8 
TU/µl (ROCK2shRNA1.0, n=11).  




(C) Analysis of motor endurance on a rotarod at two and four weeks after 6-OHDA and AAV.shRNA injection 
with groups as LAA/PBS (n=10), 6-OHDA/PBS (n=10 at two and n=8 at four weeks after lesion), 6-OHDA/control-
shRNA (ctrl-shRNA, n=10), 6-OHDA/ROCK2-shRNA in a titer of 0.25x 10
8 
TU/µl (ROCK2-shRNA0.25, n=12), 
OHDA/ROCK2-shRNA in a titer of 1.0x 10
8 
TU/µl (ROCK2-shRNA1.0, n=11). 
(D) Catwalk XT gait analysis revealed significant differences in motor coordination in the parameter Max 
Intensity At [%] at four weeks after the intracranial injections. Displayed groups are LAA/PBS (n=10), 
6-OHDA/PBS (n=8), 6-OHDA/control-shRNA (ctrl-shRNA, n=10), 6-OHDA/ROCK2-shRNA in a titer of 0.25x 10
8 
TU/µl (ROCK2-shRNA0.25, n=12), OHDA/ROCK2-shRNA in a titer of 1.0x 10
8 
TU/µl (ROCK2-shRNA1.0, n=11). 
Data for all behavioral tests are given as means ± SEM with *P<0.05, **P<0.01, ***P<0.001 (One-way-ANOVA 
with Dunnett´s test compared to control-shRNA or to vehicle group). 
 
3.3. Effect of long-term ROCK modulation on synaptic vesicle dynamics 
in vitro 
To further characterize the molecular role of ROCK in synaptic vesicle dynamics, 
mature primary hippocampal neurons were treated with the pharmacological ROCK inhibitor 
fasudil for 5 consecutive days. Via electrical field stimulation, cells were forced to execute 
transmitter release, which consists of fusion with the pre-synaptic membrane and the 
recycling of the vesicles by endocytosis. By imaging the amount of exo- and endocytosed 
vesicles the movement kinetics and released vesicle amounts after fasudil treatment were 
analyzed.  
 
3.3.1. Fasudil treatment has no negative effects on cell viability on DIV15 
To exclude toxic effects of fasudil application in a concentration of 20 µM on primary 
hippocampal neurons after 5 DIV treatment, a toxilight assay was performed. Therefore the 
amount of adenylate kinase (AK), a protein released from dying cells, was measured in the 
medium of each sample and compared between the two groups for 3 independent cultures 
at DIV15 after 5 days of consecutive fasudil treatment (from DIV11-15). No increased toxicity 
after fasudil treatment was observed (Figure 3.3/1). 
 
 




                                          
Figure 3.3/1: Analysis of toxicity after fasudil treatment for 5 consecutive days. The statistical evaluation 
resulted in no toxicity differences between the untreated and the fasudil treated condition (n=3). Data are 
given as means ± SEM (One-way-ANOVA with Dunnett´s test compared to control). 
 
3.3.2. Pharmacological ROCK inhibition alters synaptic vesicle dynamics in vitro 
To investigate the molecular effects of pharmacological ROCK inhibition on synaptic 
vesicle dynamics, primary hippocampal neurons were cultured for 14-15 DIV to generate a 
mature culture system with a distinct synaptic network of neurons. Fasudil treatment was 
performed on DIV10 by adding the substance into the medium. By stimulating the cells with 
alternating electrical fields of 20 Hz for 30s transmitter release occured and the amount of 
membrane docking and recycled vesicles could be observed using an antibody-conjugated 
fluorophore (Atto647N), which is taken up into the cells via endocytosis. Fixation of the 
cultures after stimulation allowed the quantification of fluorescence intensity as a marker for 
synaptic activity. Negative controls were generated by incubating the cells in the presence of 
the antibody solution and the sodium channel blocker tetrodotoxin (TTX) on ice, thus the 
antibody only bound to antigens present on the cell surface. Acquisition of fluorescence 
intensity nicely illustrated less signal in not stimulated cells (Figure 3.3/2-A) compared to 
neurons, which underwent exo- and endocytosis of synaptic vesicles after electrical 
stimulation (Figure 3.3/2-C). Interestingly treatment with 20 µM fasudil resulted in a 35% 
higher mean fluorescence signal on cell surface in non-stimulated conditions compared to 
controls (normalized to control = 1 vs. fasudil = 1.35 ± 0.11 a.u., Figure 3.3/2-B), suggesting 
an effect of ROCK inhibition on the deposition of synaptotagmin1 (syt1) transmembrane 
proteins on the cell surface.  







Figure 3.3/2: Analysis of vesicle dynamics from unstimulated and stimulated primary hippocampal neurons. 
Surface staining of control and fasudil treated cells (A) depicted an increase in synaptotagmin1-
immunoreactivity after ROCK inhibition (B). Electrical stimulation led to increased fluorescence signal in 
synaptophysin-immunoreactive synaptic boutons, indicating vesicle release and retrieval (C). After fasudil 
treatment there was a significant reduction in fluorescent vesicles, indicating attenuated vesicle dynamics (D), 
compared to controls. Data are given as means ± SEM with n=12. *P<0.05, **P<0.01 (One-way-ANOVA with 
Dunnett´s test compared to untreated control). 
 
After electrical stimulation with 20 Hz over 30s, which led to action potential 
triggered exocytosis and recycling of synaptic vesicles, there was much more syt1 
fluorescence signal in synapses without fasudil treatment (Figure 3.3/2-C, upper panel), 
while pharmacological ROCK inhibition seemed to decrease the amount of syt1 labeled 
vesicles (Figure 3.3/2-C, lower panel). The amount of recycled vesicles in synaptophysin-
immunoreactive (synphy-IR) synaptic boutons after stimulation is represented by ΔF, which 




is the difference in fluorescence intensity F after stimulation (Fstim) and the surface signal 
without stimulation (F0). Comparing the fluorescence intensities from both conditions, there 
was a significant reduction in fluorescence change in the fasudil treated cultures to around 
60% of ΔF of the untreated cells, meaning that there was less vesicle release or retrieval 
after stimulation and a recycle time of 5.5 minutes (control = 2.58 ± 0.37 vs. fasudil = 1.56 ± 
0.28, Figure 3.3/2-D). Taken together the pharmacological ROCK inhibition led to enhanced 
levels of syt1 in the cell membrane, while the amount of vesicles exocytosed after electrical 
stimulation and a recycling time of 6 minutes was significantly decreased compared to 
untreated controls.  
Another way to investigate vesicle dynamics is the optical life imaging technique, 
where living cells are labeled with a dye, electrically stimulated and the cellular response is 
acquired simultaneously. The dye used is a pH-sensitive Cy5-conjugated syt1 antibody 
(CypHer), in which cells are incubated 1-2 h before the experiment. During the incubation 
time the antibody is taken up into the vesicles of the neurons by spontaneous action 
potential driven exocytosis and recycling. Because of the acidic milieu of the vesicle lumen, 
the pH-sensitive Cy5-fluorophore is glaring, while this fluorescence is quenched by 
exposition to the more alkaline extracellular tyrode buffer during exocytosis following 
stimulation. As a result of re-acidification of recycled vesicles, the fluorescence increases 
again. The pH-sensitivity of the fluorophore therefore monitors the synaptic vesicle 
dynamics in real time. 
After stimulating the neurons with 20 Hz for 30 s the decrease in fluorescence signal 
turned into an increase of fluorescence starting after the electrical stimulation has finished. 
For each phase of stimulation and the resulting vesicle movements images were taken in an 
interval of two seconds and the averaged change in fluorescence from all synaptic boutons 
per field of view could be described for each measurement as a curve as it is illustrated in 
Figure 3.3/3-A. The descending course of the curves offered valuable cues about the vesicle 
kinetics during exocytosis after stimulation while the ascending part described the kinetics of 
membrane recycling and vesicle re-acidification. To estimate possible alterations in vesicle 
kinetics, exo- and endocytosis were analyzed separately by calculating the exponential fit for 
decay (exocytosis, Figure 3.3/3-B) or for rise to maximum (endocytosis, Figure 3.3/3-C) for 
each curve. Functions used to find the exponential fit were: f=y0+a*exp(-b*x) for 
exponential decay and f=y0+a*exp(b*x) for exponential rise. 




Next, the time constant τ was defined, describing the time an exponential decay 
needed to reach around 36.8% (1/e) of the initial value. τ also specified the time an 
exponential rise required to reach around 63.2% of the maximum value. Comparing mean τ 
for fluorescence decay from the group treated with fasudil to the untreated controls 
resulted in no changes in the kinetics for exocytosis of synaptic vesicles (control = 7.59 ± 1.06 
s vs. fasudil = 9.61 ± 1.74 s, Figure 3.3/3-D). The averaged time constant for the rise of 
fluorescence signal revealed no differences in kinetics of recycled vesiclesas well (control = 
19.69 ± 5.62 vs. fasudil = 15.88 ± 5.06 s). Therefore fasudil treatment is not altering the 
synaptic vesicle kinetics during exo- and endocytosis, but affecting the amount of vesicles 
exocytosed after stimulation (see Figure 3.3/2-C+D). 
 
 
Figure 3.3/3: Analysis of exo- and endocytotic kinetics in primary hippocampal neurons after electrical 
stimulation. In A an exemplary curve of CypHer fluorescence change is shown related to the time. The 
descending part of the curve is describing exo- and the ascending part endocytosis. The averaged exponential 
fit from the mean fluorescent value per time point is illustrated as line in B for the control cultures (upper 
panel, n=20) and for fasudil treated cells (lower panel, n=18). Same is shown in C for exponential rise, indicated 
with red line for untreated (upper panel, n=15) and for fasudil treated cultures (lower panel, n=10). From each 




exponential fit per measured view field τ was calculated but resulted in no statistically relevant changes, 
neither for exo- nor for endocytosis after fasudil treatment (D). Data are given as means ± SEM (One-way-
ANOVA). 
 
3.3.3. Fasudil treatment leads to a shift in G-/F-actin ratio 
To understand the molecular mechanisms of how pharmacological ROCK inhibition 
via fasudil treatment is modulating the synaptic vesicle cycle in primary hippocampal 
neurons, the actin cytoskeleton - one of the main ROCK downstream targets – was further 
examined. The actin filaments build an intricate network, which interacts with vesicles at the 
active zone. Because ROCK is one of the key modulators for assembly and disassembly of 
filamentous actin, the effect of ROCK inhibition on the amount of filamentous F-actin and 
free globular G-actin was investigated. To this, the actin filaments were separated from 
G-actin by ultracentrifugation, than depolymerized into G-actin monomers and the amount 
of G-actin was evaluated by performing western blot analysis. Blotting of actin resulted in 
much higher band intensities for globular actin, compared to the amount of filamentous 
actin (Figure 3.3/4-A). 
                        
Figure 3.3/4: Western blot analysis of G- and F-actin amount in primary hippocampal neurons with and without 
fasudil treatment. Band intensities of actin indicated a strong shift to less F- and more G- actin in fasudil treated 
cells (A), confirmed by the quantification of actin band intensities and calculation of the G-/F-actin ratio (B, 
n=1). 
 




To neglect possible variability in total actin amounts, the G-/F-actin ratio was 
calculated. The quantification of band intensities showed a massive change in the G-/F-actin 
ratio revealing more globular and less filamentous actin in the fasudil treated sample (Figure 
3.3/4-B). Unfortunately, because of problems in growing of the cell culture, there was only 
one culture available to evaluate the actin amounts. The analysis indicated a clear 
disassembly from F-actin to G-actin after ROCK inhibition via fasudil treatment, however has 



























The cure of neurodegenerative diseases is one of the main goals in today’s 
neuroscience research. One of the main obstacles is the delayed diagnostics in relation to 
the molecular pathology. In Parkinson’s disease (PD), for instance, the damage at the 
neuronal level is quite pronounced at the time when the first motor symptoms are 
recognized (Bernheimer et al., 1973). However, the complexity of normal cellular functions, 
its role in aging and during the generation of pathological features, still remains elusive. 
In PD, several neuropathological mechanisms have been elucidated such as protein 
mutations, protein misfolding and aggregation, excitotoxicity, oxidative stress and glial 
infiltration. However, whether these mechanisms are cause or consequence still remains 
unknown (Dauer & Przedborski, 2003; Dickson et al., 2009). There is a growing body of 
evidence that the inhibition of the ROCK pathway could prevent the progression of neuronal 
degeneration by antagonizing apoptotic cascades, stimulating intrinsic survival as well as 
facilitating neuronal regeneration in the affected neurons in vitro and in vivo (Raad et al., 
2012; Tönges et al., 2011; Shi & Wei, 2008). Additionally, ROCK inhibition influences the 
development of reactive astrogliosis and inflammation, thereby protecting neurons from 
degeneration (Lau et al., 2012; Villar-Cheda et al., 2012). All these beneficial properties of 
ROCK inhibition suggest that it is a promising candidate for the treatment of PD and other 
neurodegenerative disorders. 
 
4.1. Is there intrinsic regenerative capacity or a regeneration failure in 
Parkinson’s disease? 
In order to estimate the potential impact of ROCK inhibition in PD patients there was 
the primary need to determine ROCK expression levels in the human brain. Additionally, the 
question arose whether the expression level of ROCK is altered in PD and if it thereby affects 
the disease progression or regeneration. On the other hand, the expression level of the 
growth-associated protein GAP-43 could indicate a potential regenerative capacity in the 
affected brain structures. Therefore, we investigated in post mortem tissue, whether 
alterations in the expression levels of ROCK2 and GAP-43 showed evidence for 




compensatory regenerative responses or if these proteins are potentially indicating a 
regeneration failure in PD. However, examination of proteins in human brains, from both 
control brains as well as from brains with neuropathology, always comes with the difficulty 
of a large interindividual variance. Therefore, studies of human brain tissue are more difficult 
to standardize than evaluations of well-controlled animal tissue and have to be interpreted 
with caution. 
 
4.1.1. The investigated brain sections mirror characteristic features of PD 
The immunohistochemical analysis of TH in the present brain sections confirmed that 
in the majority of the PD cases, there was a pronounced degeneration of dopaminergic 
neurons. However, the TH signal in the striatum depicted that several individuals from the 
age-matched control group (non-PD) also seemed to have a lower striatal dopaminergic fiber 
density as compared to young controls. This confirmed findings from other groups, who 
showed a linear decline in striatal dopaminergic projections during healthy aging by studying 
the abundance of dopamine transporters (DAT) in the striata of people in the age range from 
18 to 88 using PET scan and SPECT imaging (Volkow et al., 1990; van Dyck et al., 2002).  
On the other hand, our study did not show dopaminergic neuron loss in the 
substantia nigra (SN) in individuals of either the young or the age-matched control group in 
contrast to PD cases. This coincides with data from the recent literature showing that 
neuronal cell death is not a characteristic feature of healthy aging (Morrison & Hof, 1997; 
Seibyl et al., 1995; Pakkenberg, 2004). Concerning our data on TH-immunoreactivity (TH-IR), 
there seemed to be a trend towards selective vulnerability of dopaminergic terminals in the 
striatum already in the aged brain, while the dopaminergic cell bodies were still unaltered. In 
PD cases the nigral dopaminergic cell death was quite pronounced, representing one of the 
main pathoanatomical characteristics of PD, but it was not reflected by significant decline in 
TH-IR fibers in the striatum. Thus, the decrease of dopaminergic neurons in the SN seems to 
be less age-related, while there is evidence for an age-depended decline of dopaminergic 
terminals, which is much more pronounced in PD disease patients. This supports the notion 
of a retrograde axonal degeneration and argues in favour of a stronger susceptibility of 
dopaminergic terminals. 




One characteristic accompaniment of neurodegeneration is the generation of glial 
scar tissue (Maragakis & Rothstein, 2006). Once CNS damage occurs, astrocytes are engaged 
to seclude the injury side from healthy tissue (Silver & Miller, 2004), which, however, 
constitutes simultaneously the major impediment to neuronal regeneration (Yiu & Zhigang, 
2009). Interestingly, studies from Mirza and colleagues (Mirza et al., 2000) did not reveal 
changes in astroglial reaction (GFAP-IR) in the SN or the striatum in PD cases compared to 
age-matched controls. In our analysis, we obtained similar results showing no differences in 
the GFAP amount of age-matched controls and PD cases in the SN. The addition of a young 
control group illustrated that there seems to be an age-related astrocytic proliferation in the 
SN, which is not reaching significant levels and is not intensified in PD cases. On the contrary, 
regarding the GFAP-IR amounts in the striatum, the analysis of young controls showed 
almost no presence of astrocytes, while age-matched controls and PD patients depicted 
abundant GFAP-IR expression. From our point of view, there seems to be an age-dependent 
proliferation of activated astrocytes in the SN as well as in the striatum, which might be 
caused by age-related sporadic neuronal impairments (Morrison & Hof, 1997; Pakkenberg, 
2004). However, it is not clear, if the striatal dopaminergic fiber loss can be correlated to 
higher amounts of astrocytic proliferation, which might transform to detrimental reactive 
astroglia, or if this in turn is a consequence of degeneration. 
Interestingly the immunohistochemistry against the microglial marker Iba1 depicted 
no relevant differences in the presence of miroglia in the striatum of PD cases compared to 
controls. There are rather a few single individuals featuring a high amount of Iba1-IR in the 
young control and the PD group, suggesting a specific micoglial reaction and transient 
proliferation to undefined cues in the respective cases. However, not primarily the amount 
of microglia is important, but their state of activation (Barcia et al., 2012). PET studies of 
Ouchi and colleagues revealed a correlation of dopaminergic cell loss and the increase of 
activated microglia in the basal ganglia of PD patients (Ouchi et al., 2005). Therefore, in the 
case of neuronal tissue damage, activated or phagocytic active microglia may deliver trophic 
factors and remove cell debris as a requirement for tissue restoration (McGeer & McGeer, 
2008). Then again, proinflammatory cytokines decrease the beneficial phagocytic activity 
and commit macrophages to an inflammatory response (Hanisch & Kettenmann, 2007; 
Hunter et al., 2007). Thus, by staining microglia in human brains with an antibody against 
Iba1, merely indicates possible activation and transient proliferation of microglia into 




damaged tissue, but gives no further information about their beneficial or detrimental 
features, mirroring only the cellular composition in the hours of death.  
Taken together, the immunohistochemical characterisation of the present human 
brain sections from PD cases, young and age-matched controls confirmed the dopaminergic 
degeneration in the nigrostriatal system during PD. This was accompanied by striatal 
astrogliosis that in turn seemed to be an age-related feature, raising the idea of constituting 
a prerequisite for the development of PD. Nonetheless, the interindividual variances did 
complicate the unification and the interpretation of the results, which are generated from 
averaged values per group. 
 
4.1.2. GAP-43 and synaptophysin expression are altered in the nigrostriatal 
system in PD 
In order to determine the general regenerative capacity of the nigrostriatal system, 
the expression level of the growth associated protein GAP-43 was examined in the brains of 
PD cases, young and age-matched controls. Due to the fact that the striatal TH-labeling 
resulted in a diffuse tissue staining, TH-positive fibers could not be clearly separated. 
Therefore co-labeling of GAP-43 and TH-IR fibers was not feasible and thus, the total striatal 
GAP-43 protein expression was analyzed. GAP-43 is associated with the neuronal 
development and is mainly present in neuronal growth cones and immature synapses, 
however levels decline precipitously by the completion of mature synaptic networks (Frey et 
al., 2000; Neve et al., 1988). Interestingly, the immunohistochemical analysis of GAP-43 
revealed quite distinct expression levels with heterogeneous distribution in the human 
striatum. Comparing the protein levels between PD cases and controls resulted in no 
expression differences between the groups. Therefore, dopaminergic degeneration seems to 
have no influence on GAP-43 expression levels in the striatum of PD patients, indicating no 
compensatory sprouting from adjacent neuronal tissue. This observation goes in line with 
findings from Iwata and colleagues employing the 6-OHDA rat model, where striatal 
intoxication and dopaminergic degeneration was not followed by changes in the GAP-43 
protein expression (Iwata et al., 2001). Taking into account the results from a parallel study 
with Dagmar Galter from the Karolinska Institute in Sweden, there were also no detectable 
changes in the striatal GAP-43 mRNA in situ signal of PD cases and controls (manuscript in 




preparation). Thus, we assume that the degeneration of dopaminergic terminals is not 
reflected by changes in GAP-43 expression. However, the dynamic processes of neuronal 
plasticity or reorganisation and sprouting could also imply a short-term up-regulation of 
GAP-43, suggesting a transient increase as a consequence of dopaminergic degeneration. 
Therefore, transient changes in expression could not have been detected in the present 
analysis of post mortem tissue, where dopaminergic degeneration started a long time before 
the observation. Interestingly, the averaged synaptophysin immunoreactivity (synphy-IR) 
appeared unchanged in PD cases as well, even though there were quite high interindividual 
differences in the PD group. In two of the examined PD cases the drastic reduction of 
synaptophysin-IR could indicate a constant decrease of the synaptic compartment, caused 
by the degeneration of dopaminergic synaptic connections. Therefore, further analysis of a 
specific dopaminergic synaptic marker, such as the vesicular monoamine transporter 
(VMAT), could be used to determine the decline of especially striatal dopaminergic synapses 
(Miller et al., 1999; Okamura et al., 2010). 
The evaluation of GAP-43 protein expression in the SN revealed only a sparse 
immunofluorescent signal in co-labeled TH-IR neurons. This finding was not surprising, 
because GAP-43 protein expression is assumed to be likely present in the neuronal 
terminals. Nevertheless, the trend of decreased GAP-43-IR signal in dopaminergic neurons of 
PD cases goes in line with findings from Dagmar Galter, who provided evidence for 
significantly decreased GAP-43 mRNA expression levels in dopaminergic neurons of PD 
patients. She demonstrated that in most of the remaining dopaminergic neurons of PD cases 
the GAP-43 mRNA signal was virtually absent, while controls exhibit GAP-43 mRNA signal in 
different amounts (manuscript in preparation). Same, Iwata and colleagues found out by 
studying GAP-43 mRNA amounts in dopaminergic neurons after intrastriatal 6-OHDA 
intoxication in rats, suggesting that the lack of GAP-43 mRNA expression resulted from 
neuronal damage and restricted cellular functioning of the transcription machinery (Iwata et 
al., 2001). 
Furthermore, we could observe a significantly decreased synaptophysin-IR in the 
SNpc in PD cases constituting nigral presynaptic disintegrity, which might be caused by the 
distinct death of postsynaptic neurons. Interestingly, this decrease in presynaptic protein 
seemed to be an apparent feature in age-matched controls as well, however not reaching 
significant levels. In turn, this finding coincides with what is known from the present 




literature, confirming that characteristic features of aging are not represented by neuronal 
cell death. Age dependent synaptic changes are rather composed by region-specific loss in 
dendritic branching and spine density, probably caused from the higher vulnerability of 
certain cell types to environmental changes (Burke & Barnes, 2006; Morrison & Hof, 1997). 
Taken together the decrease in GAP-43 protein revealed mild indication for impaired 
intrinsic regenerative capacity of dopaminergic neurons, while the decline of GAP-43-IR 
structures in the adjacent nigral neuropil seemed to be an age-related feature. Additionally, 
the presynaptic decline in the SN appeared to be age-dependent, however its significant 
diminution was restricted to PD. 
 
4.1.3. There is diffuse ROCK2 expression in the nigrostriatal system of the human 
brain 
In the present study, we demonstrated for the first time that there is ROCK2 
expression in the human nigrostriatal system. The evaluation of ROCK2 immunoreactivity 
(ROCK2-IR), however, revealed only sparse expression throughout the SN and the striatum. 
Next to a weak diffuse tissue staining, ROCK2-IR occurred in conspicuous puncta-like 
structures that seemed to be distributed intracellularly and in the extracellular matrix of the 
tissue. The same punctate ROCK2 staining González-Forero and colleagues described to be 
present in hypoglossal motoneurons of rats, suggesting that ROCK2 is primarily expressed in 
neurons (Gonzalez-Forero et al., 2012). However, in the SNpc of human brains we could not 
allocate the ROCK2-IR to specific cell types or particular localisation in the cells. Measuring 
the ROCK2-IR in dopaminergic neurons of the SN resulted in no changes in the expression 
levels between PD cases and both control groups. Approximately the same averaged ROCK2 
amounts were quantified in the nigral neuropil, showing no evidence for a different 
expression pattern in PD cases or age-matched controls. These findings suggest that the 
mean expression of ROCK2 is not altered in the SNpc in PD, at least not at the time point of 
death. Therefore there seems to be no elevated inhibitory signalling, at least not propagated 
through the ROCK2 pathway, which could be responsible for regenerative failure. However, 
there was one single case from the age-matched group that showed a noticeable high 
amount of ROCK2 expression in the nigral neuropil. Having a closer look at ROCK2 expression 
in the striatum, the overall analysis depicted that the same case expressed ROCK2 in very 




weak amounts in the putamen in comparison to the other age-matched controls. On the 
contrary, there was one PD case, which possessed very high ROCK2-IR in the putamen. These 
outliers suggest that ROCK2 expression might be a very dynamic process, which is up- or 
downregulated by particular external or internal cues. Consulting the literature to ROCK2 
expression after neuronal lesion in humans, there is evidence for the upregulation of the 
ROCK upstream regulator Rho (A+B) directly after traumatic brain injury, suggesting 
presumable involvement of the ROCK2 signalling cascade as a consequence of neuronal 
damage (Brabeck et al., 2004). However, the expression level alone cannot directly be 
correlated to kinase activity. The ROCK2 activity state attributes to either be inactive with 
perinuclear localization or to be translocated to the plasma membrane upon Rho activation 
(Shi & Wei, 2008). In the present study of human brain tissue, ROCK2 expression could not 
be allocated to a particular localization. Thus, there seems to be no correlation between 
ROCK2 expression and advanced PD or aging.  
 
4.1.4. ROCK2 expression is altered in striatal astrocytes and microglia 
Although there were high interindividual disparities, the quantification of single 
striatal cells, which revealed increased ROCK2-immunofluorescent signal, indicate a strong 
evidence for the upregulation of ROCK2 expression in particular cells in the striatum of PD 
cases. Interestingly, this phenomenon was also quite pronounced in age-matched controls, 
however not reaching significance levels. We can assume that in PD and aging there are 
elevated numbers of cells showing highly expressed ROCK2, potentially correlated with 
enhanced ROCK2 activity. Interestingly, it turned out that in the group of PD cases these cells 
seemed to be primarily astrocytes and microglia, contradicting the assumption of Gonzàlez-
Forero and colleagues, that ROCK2 is predominantly expressed in neurons of the vertebrate 
brain (Gonzalez-Forero et al., 2012). The relationship between increased ROCK2 and the 
higher number of astrocytes in the striatum of PD cases remains ambiguous and reinforces 
the role of glia in PD. Therefore, it is not clear whether an abnormal activation of the ROCK2 
pathway in astroglia occurs in PD or if this ROCK2 upregulation is due to transient cellular 
alterations to modulate the cytoskeleton, cellular migration and proliferation via the ROCK 
pathway. Because the age-matched controls exhibited the same trends in numbers of ROCK2 
upregulating astrocytes, this phenomenon seemed to be age-related as well, however being 




intensified in PD. The similar finding of exhibiting a trend towards increased numbers of 
ROCK2-IR microglia in PD cases confirms the strong suspicion of involvement of both glial 
types in disease progression. For example, Barcia and colleagues demonstrated in a rat 
model, that MPTP intoxication enhanced ROCK activity, which in turn is associated with the 
activation of microglia cells, characterized by morphological changes (Barcia et al., 2012) and 
increased microglial ROCK2 expression (Villar-Cheda et al., 2012). Upregulated ROCK2 
expression therefore provides evidence for an inappropriate microglial activity in PD 
patients. 
In this context and in finding treatment strategies to arrest the progressive 
dopaminergic cell death or to facilitate nigrostriatal restoration in PD, pharmacological ROCK 
inhibition would become highly important. It is already known that ROCK inhibition exerts 
beneficial effects on brain injuries by attenuating glial scarring (Mueller et al., 2005). 
However, to what extent the infiltration of reactive astrocytes, the so called astrogliosis, or 
the final scar formation might be deleterious for neurons, remains elusive. Moreover, in 
lesion paradigms, astrocytes are known to constitute a physiological wall, therefore being 
partially responsible for the regeneration failure (Silver & Miller, 2004). Investigations by Lau 
and colleagues about the effects of ROCK inhibition on cultured astrocytes showed that 
pharmacological ROCK inhibition evoked transcriptomic changes and cytoskeletal 
reorganization, which are consistent with astrocytes that adopted a physiologically beneficial 
phenotype. Furthermore, the expression levels of the brain derived neurotrophic factor 
(BDNF) or the excitatory amino acid transporter (EAAT) where upregulated, while the 
expression of the semaphorins SEMA4B and SEMA5A as well as the ephrin/Eph complexes 
ephrin-A/EphA and ephrin-B/EphB, which are supposed to transmit inhibitory guidance cues 
to neurons (Goldberg et al., 2004; Goldshmit et al., 2006), were dramatically decreased (Lau 
et al., 2012; Lau et al., 2011). Investigations from our group in the SOD1-G93A mouse model 
of ALS showed significantly reduced astroglial scar tissue in the affected area of the CNS 
after oral fasudil treatment compared to untreated animals at an intermediate time point 
during disease progression (Tönges et al., 2014). Furthermore, the activated microglia 
infiltration was significantly increased in the same fasudil treated animals and was 
considered to be involved in neuroprotective activities in the early stages of the disease 
(Tönges et al., 2014; Henkel et al., 2009). This was confirmed in a cytokine release paradigm 
in vitro, where ROCK inhibition via fasudil treatment led to a pronounced attenuation in the 




release of inflammatory cytokines and chemokines from cultured microglia, which were 
stimulated by the addition of lipopolysaccharides (LPS) (Hunter et al., 2007; McGeer & 
McGeer, 2008; Zhao et al., 2011). In addition, by employing the MPTP mouse model of PD, 
Barcia and colleagues discovered that activated microglia formed intercellular contacts with 
the damaged dopaminergic neurons, involving reorganisation of the actin cytoskeleton and 
are thereby enable to engulf the damaged dopaminergic neuron, suggesting the formation 
of a microglial phagosome. They could show that ROCK inhibition blocked microglia 
migration and thereby prevented possible unnecessary elimination of attacked 
dopaminergic neurons by inhibiting the microglial cytoskeletal rearrangement (Barcia et al., 
2012). 
Taken together, we could show that dopaminergic degeneration is accompanied by a 
decrease in GAP-43 and synaptophysin protein expression in the neuropil of the SNpc in PD 
cases, however, this phenomenon was also present in age-matched controls. Additionally, 
there is strong evidence for the involvement of increased ROCK2 expression in astrocytes 
and microglia during PD progression. Furthermore, it seems that the diminution of synaptic 
plasticity and neuronal regenerative capacities, as well as the upregulation of glial ROCK2 
expression in the striatum are age-related processes, which might be accelerated in PD. 
However, this study could not clarify whether such changes in protein expression are 
involved in the pathological process or are merely a consequence of dopaminergic 
degeneration, due to the fact of mirroring only the state of protein expression and cell 
composition in the terminated hours of life, disregarding fluctuations weeks, months, or 
years before. Nevertheless, the results from the present study, together with the knowledge 
about the role of ROCK inhibition on neuronal survival, regenerative outgrowth and in 
modulating glial formation, foster the role of pharmacological ROCK inhibition in the 










4.2. The role of neuronal ROCK inhibition in the 6-OHDA mouse model of PD 
 
The pharmacological inhibition of ROCK emerged as being a promising target in the 
treatment of different aspects linked to neuronal survival, regeneration and modulating glial 
infiltration in diverse models of neurodegeneration. Advantages of the ROCK inhibitor fasudil 
comprise the possibility that it can be applied orally, crossing the blood brain barrier and 
reach virtually all cell types in the nervous tissue (Mueller et al., 2005; Tatenhorst et al., 
2014). Nevertheless, one drawback of the application of this kinase inhibitor is its 
incomplete specificity for ROCK2, inhibiting both ROCK isoforms and other kinases (Davies et 
al., 2000; Mueller et al., 2005). To ascribe the protective properties specifically to the 
inhibition of ROCK2 and to exclude effects from blocking other kinases, we used a virus-
mediated RNA-interference approach by unilateral expression of a small hairpin RNA 
(shRNA) in the SN of 6-OHDA intoxicated mice. The usage of vectors containing the neuron 
specific human synapsin promoter for the expression of the fluorophore and the unspecific 
polymerase H1 promotor for the transcription of the ROCK2-shRNA enables to identify 
transduced neurons by the expression of the fluorophore. This expression was confirmed to 
be exclusively neuronal by immunohistochemistry. By employing the AAV2 serotype, ROCK2-
shRNA expression was targeted preferentially to neuronal cells, which therefore nearly 
excluded effects of kinase inhibition from glia cells (Tenenbaum, 2004; Bartlett et al., 1998). 
It is thus important that the observed effects are attributed almost exclusively to ROCK2-
downregulation in neurons of the SNpc. The effective knockdown of the target protein 
ROCK2 with the used vector was previously confirmed by Western blot analysis of infected 
primary midbrain neuronal cultures (Saal et al., 2015) as well as by real-time PCR of infected 
cultured retinal ganglion cells (RGC), resulting in 75% reduction of the ROCK2-mRNA after 
7DIV and in vivo by immunohistochemistry against ROCK2 in RGC at two weeks after 
intravitreal virus injection (Koch et al., 2014). 
To evaluate the protective effects of neuronal ROCK2 downregulation, we chose the 
6-OHDA striatal lesion model to induce progressive retrograde degeneration of the 
dopaminergic nigrostriatal projections, which best resembles the progression of PD (Alvarez-
Fischer et al., 2008). Viral vectors were injected simultaneously with 6-OHDA to mimic a 
therapeutic approach during the disease progression. Employing the 6-OHDA model offered 
the possibility to spatially separate AAV-mediated ROCK2 inhibition in nigral dopaminergic 




somata from the toxin-induced degeneration of striatal dopaminergic terminals. The 
observation time period of four weeks enabled the advanced dopaminergic impairment by 
anticipating spontaneous regeneration (Walsh et al., 2011; Schwarting & Huston, 1996) 
distinguishing the effects of ROCK2 inhibition on neuronal degeneration. 
 
4.2.1. shRNA mediated ROCK2 downregulation increases dopaminergic survival 
after 6-OHDA intoxication 
Four weeks after the injection, stereologically obtained numbers of TH-positive 
neurons in the SN of the non-intoxicated vehicle control group were similar to the results 
previously obtained in the non-intoxicated vehicle control groups of the 6-OHDA model 
(Tatenhorst et al., 2014) and of the MPTP model (Tönges et al., 2012). Therefore we 
conclude that the mechanical damage caused by the nigral injections alone is negligible. 
Since previous reports suggested toxic effects by long-term expression of shRNA-vectors in 
vivo (Blits et al., 2010), two AAV dosages were compared. Interestingly, the lower titer (0.25x 
108 TU) was more effective in attenuating 6-OHDA-mediated dopaminergic neuronal death 
than the higher titer (1.0x 108 TU). In contrast to previous studies of our group, where oral 
treatment with fasudil showed no protective effect on TH-IR cells after 6-OHDA lesion 
(Tatenhorst et al., 2014), we could, in the present study, definitely assign the attenuated 
dopaminergic cell loss to the intrinsic shRNA-mediated ROCK2-inhibition. Although we did 
not observe overt toxicity, it is possible that the higher titer AAV.shRNA exerted unspecific 
toxic or off-target effects, which attenuated the protective effects of ROCK2-inhibition. Li 
and colleagues could show that activated ROCK is directly phosphorylating PTEN (Li et al., 
2005), thus we can assume that specific shRNA mediated inhibition of ROCK2 is enhancing 
dopaminergic survival presumably through the PTEN/Akt/mTOR pathway (Tönges et al., 
2011; Kim et al., 2011). A previous study from our group showed, that shRNA mediated 
ROCK2 downregulation increased cell survival and decreased axonal degeneration of RGCs in 
the rat optic nerve crush model with the same viral constructs as used in the present study 
(Koch et al., 2014). Here we could assign the beneficial effects to the activation of the Akt 
pathway and through the decreased activity of the protease caspase-3, which is an essential 
player in the apoptosis cascade (Porter & Jänicke, 1999). 




Quantification of Nissl-positive cells revealed that the declined number of neurons 
was similar to the loss of TH-IR cell numbers. This indicated that 6-OHDA induced a specific 
dopaminergic cell death and we thus could assume that there is no misleading 
downregulation of TH as a consequence of 6-OHDA effects (Georgievska, 2002). While the 
histological quantification of striatal TH-IR fibers still identified ~40% remaining axons in the 
lesion control, as compared to the vehicle injected animals at four weeks after lesion, the 
levels of dopamine and its metabolites in the HPLC analysis were reduced more severely. 
The significant fiber loss of approximately 60% corresponds to the amount of nigrostriatal 
degeneration in PD when the first motor symptoms manifest (Blum et al., 2001). However, in 
the present study, it seemed that there was a strong trend in attenuated dopaminergic fiber 
loss from shRNA-mediated ROCK2 downregulation, which was not significantly increased in 
comparison to the adequate shRNA control. Interestingly, in case of the low virus titer the 
fiber degeneration was just significantly alleviated in comparison to the 6-OHDA lesion only 
control (*p = 0.05; because this is not the adequate vector control, we did not add this 
information to the results). This indicates an attenuation of the 6-OHDA effect propagated 
through intracellular ROCK2 downregulation, leading to a mild preservation of axon terminal 
morphology and of TH integrity in ROCK2-shRNA injected mice. However, this finding did not 
translate into similarly increased levels of dopamine or its metabolites HVA and DOPAC, 
which references to advanced impairments of terminal functionality caused by 6-OHDA. 
Similar results were found in our previous study by having a strong decline of dopamine and 
its metabolites four weeks after 6-OHDA lesion and consecutive oral fasudil treatment 
(Tatenhorst et al., 2014). In the study from Kim and colleagues the direct modulation of the 
survival cascade propagated through mTOR by intranigral injection of AAV-mediated Rheb 
(activator of mTOR) expression in the 6-OHDA mouse model, resulted in enhanced survival 
and preservation of the dopaminergic terminals and their functionality. They showed that 
the striatal TH-density and levels of dopamine and HVA after 6-OHDA lesion were virtually 
completely preserved, however virus mediated gene expression was started three weeks 
before the lesion (Kim et al., 2011). In contrast to our study, the Rheb gene expression was 
strongly increased at the time point of intoxication, which can explain the pronounced 
effects. In our experiments, the simultaneous injection of 6-OHDA and the ROCK2-shRNA 
lead to delayed expression of the shRNA (Koch et al., 2011; Shevtsova et al., 2005), while the 
6-OHDA impact on the dopaminergic neurons is immediate. It is likely that this deferred 




downregulation of the target gene results in delayed activation of survival promoting 
pathways, consequently leading to advanced toxic effects on dopaminergic neurons. Taken 
together, this indicates that shRNA-mediated ROCK2 downregulation intrinsically protected 
the remaining neurons from degeneration. This would explain the morphological 
maintenance of dopaminergic terminals, while concurrently there is still functional 
impairment (Georgievska, 2002). 
 
4.2.2. Neuronal ROCK2 downregulation has only minor effects on behavioral 
outcome 
The total dopamine depletion observed with HPLC was additionally mirrored in the 
apomorphine turning test. The strong rotation behavior induced by the apomorphine 
injection in all 6-OHDA-lesioned animals at two weeks after lesion was even more 
pronounced after four weeks. This implies a further upregulation of striatal postsynaptic 
dopamine receptors to compensate for the lack of signal transduction resulting from the 
deleted dopamine transmission in all 6-OHDA lesioned animals (Schwarting & Huston, 1996). 
As a consequence of the intraneuronal failure of shRNA-mediated downregulation on the 
preservation of dopaminergic functionality, ROCK2 inhibition could not attenuate rotation 
behavior after apomorphine application. Furthermore, behavior analyses with rotarod or the 
cylinder-rearing test were not significantly improved in animals treated with ROCK2-shRNA.  
The effects of the 6-OHDA lesion were also examined using the Catwalk XT gait 
analysis system. The high sensitivity of this method has been validated previously by 
Vandeputte and colleagues, however they could observe only one significant change in the 
parameter for intensity of the front paws after striatal unilateral 6-OHDA lesion in rats 
(Vandeputte et al., 2010). In the present study we could show that the 6-OHDA lesion 
affected gait of mice, reflected in an increased paw print size, possibly to compensate 
postural instability. Simultaneously, the parameter giving the time interval to reach the 
maximal paw print intensity related to the duration of the stand (Max Intensity At), showed 
converse results regarding the hind paws. This finding indicates an irregularity in walking 
pattern of unilateral striatal lesioned mice concerning the hind limb, which was innervated 
by the lesioned brain hemisphere, as it has been described before in rats (Hsieh et al., 2011; 
Vandeputte et al., 2010). This step irregularity was completely rescued in the mice, which 




were injected with ROCK2-shRNA (1.0x 108 TU). Thus, we could detect a significant reduction 
of 6-OHDA-induced motor impairment by ROCK2-shRNA compared to control-shRNA despite 
the lack of significant recovery in striatal levels of dopamine and its metabolites. 
Taken together, it has to be acknowledged that the specific targeting of ROCK2 
knockdown in the 6-OHDA model does not seem to reliably counteract the strong local 
oxidative damage exerted in the striatum after four weeks. While there is a morphologic 
preservation of dopaminergic cell bodies in the SNpc and a trend to reduced degeneration of 
axonal terminals in the striatum, these structures largely lack functionality and show loss of 
intact neurotransmission. This might be due to the strong toxicity of the 6-OHDA model that 
causes an immediate detrimental effect on dopaminergic fibers in the striatum (Stott & 
Barker, 2014) while the downregulation of ROCK2 after AAV injection will be effective after 
some days. Therefore, a longer observation time in a model with lower lesion severity may 
have permitted to better observe beneficial effects. Furthermore, an earlier injection time 
point of the AAV.shRNA constructs may have resulted in a prolonged ROCK2 downregulation 
and earlier activation of the regenerative response. Nevertheless, this study evaluated the 
intrinsic role of neuronal ROCK2 as a central regulator for neuronal survival following toxin-
induced degeneration, while it virtually disregarded potential extrinsic effects generated by 
microglial and astrocytic responses to neuronal degeneration. 
 
4.3. The role of pharmacological ROCK inhibition on dynamic 
presynaptic function 
Since ROCK inhibition is known to facilitate neuronal survival and axonal regeneration 
in different in vitro and in vivo studies, it is a promising target to improve the treatment of 
neurodegeneration. However, there is the necessity to fully understand different possible 
modes of action of a specific ROCK inhibitor before translation to clinical trials. As fasudil is 
one of the most promising ROCK inhibitors being already successfully employed in the 
treatment of vasospasms in humans (Shimokawa et al., 2002), we chose this substance for 
the present investigation.  
We thus examined the effect of pharmacological ROCK inhibition on synaptic vesicle 
dynamics, since the actin cytoskeleton is one of the central structures in mediating synaptic 
vesicle dynamics and is the main downstream target of ROCK signalling (Dillon & Goda, 2005; 




Ridley, 2006). Cells were incubated in fluorescently labeled antibody solution and were 
either electrically stimulated to undergo transmitter release or incubated on ice to generate 
a negative control. The addition of TTX to the antibody solution of the negative control 
prohibited the induction of action potentials and therefore minimized the spontaneous 
bursting activity of the cells (Katz & Miledi, 1967). Interestingly, the treatment with fasudil 
for five consecutive days prior to the experiment resulted in a significantly higher 
fluorescence signal in the unstimulated condition. This means that there was much more 
antibody binding to the amino terminus of synaptotagmin1 (syt1) in fasudil treated cultures 
compared to untreated controls. Due to the minimization of vesicle release to the plasma 
membrane, there should be virtually no vesicle release in the negative controls. Therefore, 
antibody-labeled structures resulted from surface staining of persistent syt1 in the outer cell 
membrane (Brose et al., 1991). It is known, that there are small clusters of remaining syt1 in 
the plasma membrane of unstimulated cells (Willig et al., 2006) and that synaptic vesicle 
proteins reside at the synaptic surface for being recaptured during endocytosis (Fernández-
Alfonso et al., 2006). In our experiments, fasudil treatment therefore seemed to enhance the 
syt1 clustering on the surface of the plasma membrane observed in unstimulated conditions. 
This increase in surface syt1 could be caused by three different mechanisms: 1. Fasudil could 
enhance the basic spontaneous bursting activity of hippocampal neurons in culture and 
therefore increase the number in exocytosed vesicles, resulting in more exposure of the 
intravesicular domain of syt1 to the extracellular space. 2. There could be fasudil-mediated 
slower or less endocytosis, which is consequently leading to increased amounts of non-
recycled vesicle proteins on the surface. 3. Long-term fasudil treatment could lead to 
enhanced expression of the syt1 protein which results in a higher surface pool. To answer 
this question, we have included the results from the experiments in which the cells were 
electrically stimulated.  
After electrical stimulation the fluorescent signal of syt1 was much brighter than in 
the unstimulated negative control, indicating that many vesicles underwent the circle of exo- 
and endocytosis (Willig et al., 2006). To investigate potential differences in the amounts of 
vesicles engaged in transmitter release and vesicle retrieval after fasudil treatment, we 
compared the fluorescence signals of cultures electrically stimulated with 20 Hz for 30 s to 
the unstimulated surface staining. For better clarification, we calculated ΔF, which displayed 
the change in fluorescence signal after stimulation subtracted by the signal of surface 




staining in the respective condition. Interestingly, the fluorescence intensity of fasudil 
treated cultures had drastically decreased, resulting in a significant smaller ΔF compared to 
untreated cells. This means that after stimulation and intensified vesicle release, fasudil 
leads to less synaptic vesicles going through the cycle of exocytosis and retrieval, compared 
to untreated cultures. Moreover, this contradicts the hypothesis of having increased 
bursting activity in fasudil treated cultures, so this in turn might be not the reason for the 
enhanced syt1 presence at the surface of cells treated with fasudil.  
In order to examine the mechanism responsible for decreased ΔF, we evaluated the 
results from the life imaging observations. Given the real-time course of exo- and 
endocytosis by measuring the changes in fluorescence generated with the pH-sensitive 
fluorophore CypHer coupled to syt1-antibody, allowed us to evaluate synaptic vesicle 
kinetics after electrical stimulation. Based on the curves generated for each stimulation 
event, we could observe similar vesicle kinetics as described before by Fernández-Alfonso 
and Ryan. They found, that the time of endocytosis during continuous stimulation with 20 Hz 
for 30 s exceeded the time of exocytosis, suggesting a rapid release of the fusion-competent 
vesicles and a slower recycling phase of these membrane-docked vesicles leading to an 
accumulation of vesicle compounds on the synaptic surface (Fernández-Alfonso & Ryan, 
2004; Ryan & Smith, 1995). Calculating the mean time constant τ as a measure for the speed 
of either exo- or endocytosis in our study, it revealed no differences between the fasudil 
treated and untreated cultures. Therefore, in fasudil treated cells the exocytosis of synaptic 
vesicles appeared to be as fast as in the untreated condition and the same seemed to be 
true for the vesicle recycling within the 5.5 minutes of observation time. From this point of 
view, the decreased amounts of incorporated antibody signal after electrical stimulation 
were not resulting from altered vesicle kinetics. The same would be true for the surface 
staining of syt1 without stimulation, when it is assumed that the same mechanisms of vesicle 
internalization are operating the endocytosis of vesicles in the resting state, where basic 
bursting activity is present, as well as membrane recycling after strong stimulation. 
Moreover, changes in the synaptic vesicle release probability are known to be due to 
the amount of fusion-competent vesicles in the so-called readily-releasable pool (RRP), 
which represents the small fraction (~1%) of vesicles conducting fast exocytosis during 
physiological activity, while the majority of vesicles remains in the so-called reserve pool (RP) 
(Rizzoli & Betz, 2004; Denker et al., 2011). During our stimulation paradigm of 20 Hz for 30 s 




we observed a steady decrease in fluorescence until the stimulation stops at 30 s. This 
indicates continuous exocytosis of synaptic vesicles, which fuse with the plasma membrane 
as response to strong electrical stimuli. To maintain continuous exocytosis, vesicle release is 
recruited from vesicles of the so-called recycling pool, which is containing 10-20% of all 
vesicles, while the majority of vesicles remains unused in the RP, even during strong 
stimulation (Rizzoli & Betz, 2004; Denker et al., 2011). Therefore, the frequent stimuli in our 
study seemed to induce permanent vesicle recycling, thus, no depletion of the recycle pool 
was reached after 20 Hz for 30 s in fasudil treated and untreated cultures. However, this 
gives no information about the number of vesicles released simultaneously in the same time, 
when we assume that the kinetics for exo- and endocytosis are not changed and the 
retrieval of vesicles from the recycling pool is maintained during stimulation. Regarding our 
results depicting a decreased ΔF in fasudil treated neurons, this suggests a reduction in the 
total number of vesicles, which were released and recycled induced by electrical stimulation 
over 30 s. This means that fasudil treatment had reduced the size of the RRP and therefore 
the amount of vesicles, which underwent the cycle of exo- and endocytosis during particular 
stimulation periods (Rosenmund et al., 1996). A similar result was found by González-Forero 
and colleagues in a patch clamp study investigating the electrical activity of rat hypoglossal 
motoneurons after ROCK inhibition. They observed a significant decrease in postsynaptic 
input after pharmacological short time (5-10 min prior to the experiment) ROCK inhibition 
with either Y-27632 or dimethylfasudil (Gonzalez-Forero et al., 2012). They could show that 
ROCK inhibition leads to a modulation of the presynaptic strength resulting in decreased 
output caused by reduced transmitter release. Electron microscopy of synaptic boutons 
revealed a reduction in number of presynaptic vesicles in two areas at the active zone, one 
directly adjacent to the membrane and the second 0.1-0.2 µm away from the active zone, 
while there was no significant reduction in the more distant region and in the total vesicle 
pool size after ROCK inhibition. This suggests a ROCK mediated modulation of the vesicle 
number in the RRP and the recycling pool. Inhibiting the pathway of ROCK mediated 
phosphorylation of MLC, which thereby also increases the activity of MLCP, leads to the 
absence of actin/myosin contractility and non-initiation of stress fiber formation (Raad et al., 
2012; Amano et al., 2010). For vesicle exocytosis, the formation of stress fibers is essential to 
provide cytoskeletal tracks to maintain the physiological guidance of vesicles to the RRP or 
from the RRP to the active zone (Dillon & Goda, 2005; Gonzalez-Forero et al., 2012). 




Additionally, during ROCK inhibition and the inactivation of LIMK, cofilin is activated and 
therefore mediating F-actin depolymerization at the pointed ends, which could interrupt the 
physiological track to transport vesicles to the membrane (Meyer & Feldman, 2002). In this 
case, there would be a shift to more globular actin (G-actin) than filamentous F-actin, which 
we tested in our study by evaluating the G-/F-actin ratio in hippocampal neurons after long-
term ROCK inhibition with fasudil. Unfortunately, there was only one culture available to test 
this hypothesis, but we could observe a distinct shift to highly elevated G-actin amounts 
after ROCK inhibition compared to untreated cultures. This gives evidence for the essential 
role of ROCK activity in maintaining the ultrastructural composition of actin filaments, which 
therefore enables vesicle recruitment from the reserve pool and the transport to the 
membrane of the active zone. Of course, the observation of increased G-actin amounts has 
to be confirmed in further experiments. 
Taken together, long-term fasudil treatment seems to decrease the ability of synaptic 
vesicles to move to the active zone and to fuse to the membrane by interrupting the 
synaptic actin cytoskeleton, which is normally providing the track for synaptic vesicle 
movements and is mediated by inactivation of cofilin. However, in our study hippocampal 
vesicle exo- and endocytosis is not reduced at all after fasudil treatment. Thus, we observed 
continuous vesicle release and retrieval during strong electrical stimulation, but the size of 
the RRP and the amount of exo- and endocytosed vesicles seem to have drastically 
decreased, while the kinetics were not altered. In regard to these findings, the enhanced 
syt1 amounts observed in the plasma membrane from the unstimulated culture conditions is 
not due to decreased endocytotic recycling of synaptic vesicle components, but further 
there might be an upregulation in syt1 expression caused by ROCK inhibition. It is 
established, that ROCK inhibition by fasudil is changing the transcriptome of astrocytes and 
alters expression levels of different astrocytic proteins (Lau et al., 2012; Lau et al., 2011). The 
same is known from inhibition of the ROCK-activator RhoA in the MN9D dopaminergic cell 
line, where Zhou and colleagues showed evidence for enhanced upregulation of synaptic 
proteins like VMAT, synaptophysin and synapsin, which was accompanied by a decrease in 
alpha-synuclein expression (Zhou et al., 2011). Therefore, the expression of synaptic proteins 
including syt1 might be upregulated by ROCK inhibition even in mature hippocampal 
synapses, but this has to be confirmed by further investigations, for instance with Western 
blot analysis or quantitative PCR. 




The role of pharmacological ROCK inhibition in synaptic transmission seems to 
influence the modulation of a complex network involving the actin/myosin contractility and 
regulation of actin filaments for vesicle trafficking. However, since fasudil is known to act as 
a “dirty” drug also affecting several other kinases (Mueller et al., 2005; Davies et al., 2000), 
other pathways and mechanisms might be involved in vesicle dynamics as well. 
Regarding the application of ROCK inhibitors in the treatment of neurodegenerative 
disorders, the present findings could be of great interest to compensate the lack of 
dopaminergic transmission in the striatum of PD patients. The loss of dopaminergic 
inhibition, which is mediated through the postsynaptic D2 receptor in the striatum, results in 
the disinhibition and overactivation of the subthalamic nucleus (STN), which causes some of 
the characteristic symptoms of PD (Parent & Hazrati, 1995; Crittenden & Graybiel, 2011). 
Furthermore, output neurons from the STN mediate excitatory innervation of the GPe, GPi, 
SNpr, pedunculopontine nucleus (PPN) and SNpc via glutamatergic transmission (Futami et 
al., 1995). Already damaged nigral dopaminergic neurons are thereby exposed to an 
extensive glutamatergic innervation through postsynaptic N-methyl-D-aspertate (NMDA) 
receptors that could cause excitotoxic damage (Olanow & Tatton, 1999; Rodriguez et al., 
1998, Figure 4.1-A). This may induce excessive intracellular calcium influx, which activates 
nitric oxide synthesis, generation of free radicals and thereby activates apoptotic 
mechanisms (Dong et al., 2009). As we observed in our in vitro study a significant reduction 
of the vesicle release after ROCK inhibition with fasudil from hippocampal glutamatergic and 
GABAergic neurons, we suggest that fasudil mediated ROCK inhibition could also play an 
essential role to decrease glutamate release from STN terminals at nigral dopaminergic 
postsynapses in PD (Figure 4.1-B). However, the modulation of synaptic RRP by ROCK 
inhibition might affect all excitatory and inhibitory synaptic structures. Therefore, 
application of ROCK inhibitors to modify specific transmitter release has to be further 
investigated for different types of synapses in different cell types of the mature brain.  




          
Figure 4.1: Illustration of pathomechanisms in PD progression and their possible attenuation by 
pharmacological ROCK inhibition. Reactive astro- and microglia damage the dopaminergic neuron via glutamate 
excitotoxicity and finally trigger apoptosis (A). Under pharmacological ROCK inhibition, astrocytes could 
generate a protective phenotype, while microglia could be inhibited in cytoskeleton reorganisation and 
migration (B). Excitotoxicity could be prevented by reduced vesicle trafficking to the active zone in 
glutamatergic presynapses and intraneuronal survival pathways could be enhanced by intrinsic neuronal ROCK 




inhibition. NM = neuromelanin, DA = dopamine, NO = nitric oxide, OH = hydroxyl radical, H2O2 = hydrogen 
peroxide, Ca = calcium, Mn = manganese, Fe = iron. 
 
4.4. Conclusion  
All three experiments illustrate the importance of the Rho kinase pathway in the 
treatment of PD. The decreasing regeneration capacity of neurons during aging together 
with additive not yet clarified pathological mechanisms lead to the characteristic neuronal 
loss in the nigrostriatal system. Nevertheless, there is a growing body of evidence for the 
employment of ROCK inhibitors as promising treatment for PD and we could show that at 
least in striatal astroglial cells the ROCK expression is altered in PD cases. Additionally, our 
investigations about the specificity of neuronal ROCK2 downregulation via shRNA and the 
potential role in transmitter release as well as the knowledge about ROCK inhibition from 
previous studies in neurodegeneration and glial modulation, support the application of ROCK 





















The cure of neurodegenerative diseases is one of the main goals in today’s 
neuroscience research. One of the main obstacles is the delayed diagnostics in relation to 
molecular pathology. In Parkinson’s disease (PD), several pathophysiological mechanisms 
participating in neurodegeneration have been elucidated, e.g. protein aggregation, increased 
oxidative stress, mitochondrial malfunction etc., but the precise etiological cascade still 
remains elusive (Dauer & Przedborski, 2003; Dickson et al., 2009). In order to prevent the 
progression of neuronal degeneration and to facilitate regeneration the potential of 
modulating the Rho kinase (ROCK) pathway is gaining recognition.  
Here we could show that there seems to be an age-dependent decrease in the 
expression of the growth associated protein GAP-43, accompanied by astroglia infiltration 
and declined synaptophysin abundance in certain brain areas, which are affected in PD. 
These age-related changes are exacerbated in post mortem PD brains, but it is still unknown 
whether this is the cause or the consequence of neurodegeneration. Furthermore, ROCK 
protein expression seems to be altered at least in striatal astrocytes, indicating a role of the 
ROCK signaling cascade in neurodegeneration. The findings of attenuated dopaminergic cell 
loss after specific shRNA mediated ROCK2 downregulation in neurons of the substantia nigra 
(SN) in the 6-OHDA mouse model of PD, showed the potential of intrinsic ROCK2 inhibition 
to promote neuronal survival. Moreover, we here evaluated the role of ROCK inhibition in 
the context of transmitter regulation. We could show that pharmacological long-term ROCK 
inhibition is attenuating transmitter release by reducing the readily releasable pool (RRP) of 
synaptic vesicles in vitro. Thus, additive detrimental effects generated by excitotoxicity from 
overactive glutamatergic synapses in the progression of PD, could potentially be antagonized 
by ROCK inhibition in the respective cells. Nevertheless, further investigations are required 
to evaluate other functions of ROCK inhibition in regard to the modulation of cytoskeletal 
rearrangements and the effects on other transmitter systems. 
Taken together, by affecting cell survival, neuronal growth, glial responses and 
transmitter release, the modulation of the ROCK pathway is a highly promising target for the 
future treatment of PD and other neurodegenerative disorders and warrants more in-depth 
pre-clinical and clinical evaluation. 
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